Report #11

Comprehensive Spinoff Investment Opportunities

19 graded upcoming separations after four completions (MSG Rangers, MiniMed's full exit, Vylor and Gentherm) and two additions (Abbott Nutrition B 2.90, National Fuel Gas's upstream spin B 2.75). Ratings move to a five-band scale on the expected return to target. Vylor's first rating is SELL, target $54, after 15 states won a temporary restraining order that freezes its dividends and buybacks. Keurig Dr Pepper's Global Coffee is upgraded to B+ (3.15) on its CEO appointment; International Paper's EMEA spin falls to B- as sale talks open. Eaton's Mobility/Dana filing gives the first standalone financials (first score B 2.90). The completed cohort's median fell 1.3% against an S&P 500 down 0.9%; Sandisk fell 33.9% after a record quarter. November has no scheduled distribution; Trinzic on January 4, 2027 is next.

COMPREHENSIVE SPINOFF INVESTMENT OPPORTUNITIES

Upcoming Spinoffs Over Next 12 Months (November 2026 - November 2027)

Analysis Date: October 31, 2026 Pricing Date: All stock prices as of October 30, 2026 close (verified daily data via yfinance and the companion site’s nightly series) unless otherwise noted.

Dating convention. The report is dated October 31, a Saturday; its pricing date is the last trading day, Friday October 30, and it is right as of that close. Anything dated October 31 (UPM → WISA’s demerger) is marked post-pricing.

Rating scale. Starting with this report, ratings use a five-band scale set on the expected return to the price target: BUY ≥ +25% with gain-to-loss ≥ 3:1 · ACCUMULATE +10% to +25% · HOLD −10% to +10% · TRIM −25% to −10% · SELL below −25%, or the case no longer holds. A rating may sit outside its band only with a stated reason. Names with no valuation are NOT RATED; a few completed names keep a legacy rating with no target until a profile values them (noted where they appear).


EXECUTIVE SUMMARY: KEY CHANGES SINCE LAST REPORT (September 30, 2026)

Completed Since Last Report

ParentSpinCoTickerDistribution DateCurrent Status
MSG Sports (MSGS → MSGK)MSG RangersMSGROctober 26, 2026✅ Form 10 effective October 9; NHL Transfer Consent Agreement signed October 23; §355 tax opinion delivered. 1 MSGR per 2 MSGS. First regular-way close $177.61 (October 27); $218.49 on October 30, +23.0%. Parent renamed MSG Knickerbockers (MSGK). Moves to Part 3.
Medtronic (MDT)MiniMed — full exitMMEDOctober 15, 2026✅ Exchange offer oversubscribed (297.5M MDT tendered; proration 18.29%); final ratio at the 4.5939 cap. Medtronic exchanged all 252,813,348 MMED shares for 55,032,401 MDT shares and now owns none. No clean-up spin. MMED stays in Part 3.
Corteva (CTVA)VylorVYLROctober 1, 2026✅ Completed the day after the last pricing date. First regular-way close $68.26 (correction: last edition printed ≈$69); $72.40 on October 30, +6.1%. Moves to Part 3.
Modine (MOD) / Gentherm (THRM)Performance Technologies → GenthermTHRMOctober 1, 2026✅ RMT closed. 0.44619 THRM per MOD share; Modine holders own 43.62%. SpinCo borrowed $250M, of which $156.0M was paid to Modine. Gentherm keeps its name and ticker. Moves to Part 3.
Toro Corp. (TORO)AI OKTOAIOKOctober 8, 2026✅ Micro-cap footnote. 1 AIOK per 8 TORO; two LPG carriers plus $45M cash; Toro keeps $25M of AIOK convertible preferred. Removed from tracking.

Major Developments

  • ⚠️ Vylor faces a second multistate lawsuit, and it has frozen its capital returns. On October 1, the day of distribution, 15 states and one sovereign sued in the Southern District of Indiana, alleging the separation was a fraudulent transfer. On October 9 the court issued a temporary restraining order. It barred both companies from paying dividends, buying back stock, or disposing of assets outside the ordinary course. On October 10 it stayed the order pending an emergency motion to the Seventh Circuit, relying on Vylor’s representation that it will not declare dividends or repurchase shares while the motion is pending (8-K, primary). That parks the Q4 dividend and the $3B buyback Vylor intended. Grade A- 3.80 → A- 3.73 (profile, within band). Rating: SELL, target $54 — first rating as a listed company. The price is 25.4% above the profile’s target, the profile’s own week-one SELL trigger (above $65) has been met, and the TRO is an event the profile’s price date predates. See Part 3.
  • ⬆️ Keurig Dr Pepper named its Global Coffee CEO, B (2.95) → B+ (3.15). Russ Torres, President & COO of Kimberly-Clark, starts November 3 (8-K October 1). Management moves off the open-search score of 2.
  • ⭐ Abbott will spin its Nutrition business (NEW, 8-K October 21). Similac, Ensure, PediaSure, Pedialyte and Glucerna, ≈$8.5B of sales, tax-free, by end-2027. CEO Daniel Salvadori. First grade B (2.90), provisional.
  • ⭐ National Fuel Gas chose a spin (board approval October 14). The Integrated Upstream & Gathering business (Seneca Resources plus gathering: ≈1.1 Bcf/d, ≈5 Tcf proved) goes out tax-free in H2 calendar 2027. NFG distributes at least 80.1% and may keep up to 19.9%. CEO Justin Loweth. Moves from exploratory to graded: B (2.75), provisional.
  • Eaton’s Mobility/Dana registration statement is public. Filed October 19, amended October 30. It gives the first standalone Mobility financials: FY2025 sales $3,140M (−10%), adjusted EBITDA $451M (14.4%), falling to 13.5% in 1H26. It confirms the $1.1B cash payment to Eaton and the 50.1% / 49.9% Eaton/Dana split. Dana’s vote is December 7, with close “around the end of Q1 2027”. First score B (2.90).
  • Flex sold $2.0B of Axiom convertible preferred and closed EPC Power. General Catalyst and Koch Equity Development bought the preferred at an implied $37.5B Axiom enterprise value (8-K October 5). EPC closed October 14, funded by $4.4B of 364-day loans that transfer to Axiom at the spin, less the preferred proceeds. Axiom’s Cloud & Power segment grew 54% in the September quarter at a 10.7% operating margin. The stock fell 21.4% in October. B+ (3.35) held; the November 2 EGM is the gate.
  • ⬇️ International Paper’s EMEA spin is now a sale-or-spin, B → B-. IP named the SpinCo DS Smith plc (London listing plus NYSE ADR) on October 14. On October 15 it confirmed preliminary sale talks after unsolicited approaches. Its Q3 10-Q shows EMEA at a $(73)M operating loss with a $1.38B goodwill impairment, and EMEA guidance withdrawn.
  • The cohort had a better month than the market, and it was a split one. 9 of 25 rose; the median fell 1.3%, against an S&P 500 down 0.9% (SPY $762.63 → $755.72). Two biotechs and two results-driven names led: TRAX +27.2% (celiac data, $200M PIPE), AMTM +20.7%, FDXF +15.2% (results beat), OCTV +14.9%. Data-center and memory names fell hard: SNDK −33.9% despite record results, CHRN −27.1%, and among the upcoming parents Modine −30.7% and Flex −21.4%. Three new post-spin lows were set (ADIG $15.22 and RNA $7.61 on October 19, FDXF $107.95 on October 21), and MRP equalled its low ($21.22, October 14). Every one recovered by month-end.
  • 🔁 The standing profiles re-rated fourteen completed names in October, most of them onto the new scale:
    • SNDK HOLD → TRIM (≈$914) — the profile proposes SELL at $860; the report uses the post-results re-strike
    • FDXF HOLD → TRIM ($112)
    • HONA BUY → ACCUMULATE ($192)
    • VGNT BUY → ACCUMULATE ($48)
    • MRP BUY → HOLD, on watch ($25), with a first grade B (2.70)
    • MICC first grade A- (3.68), HOLD
    • MFP first score B+ (3.23), TRIM $35 (report, on price)
    • New targets: MBGL $28 → $27, Q $132 → $123, SOLS $62 → $57, VSNT $42 → $36, ADIG $18 → $16, OCTV $19.50 → $19 (proposed)
    • AMTM BUY → ACCUMULATE: this one is the report’s, on price (+11% through the lag window)
  • Millrose is on watch over related-party home purchases. It disclosed 1,233 completed Lennar homes (≈$333M) bought for a rental program, plus ≈$150M of build-to-rent contracts. Hunterbrook published two short reports, and a class action and a downgrade followed. Q3 brought a $250M buyback and raised AFFO guidance. Independent-director approval and a cap are still undisclosed; the watch runs to the 10-Q (due November 9).
  • ⚠️ Sandisk printed a record quarter and fell 33.9% anyway. FQ1 revenue was $11.03B (guide $10.3–10.8B) at an 85.1% non-GAAP gross margin, with a $5.0B buyback. It closed −13.5% on October 30 alone. An 8-for-1 split trades from November 20.
  • Lag-window and market items on completed names:
    • S&P Global opened a review of a possible separation of Capital IQ (October 27): Mobility Global’s former parent is weighing a second separation (exploratory).
    • Legendary reportedly made a formal offer for Lionsgate Studios (Bloomberg, October 20; secondary).
    • Starz returned to Verizon Fios after a two-week blackout.
    • Comcast suspended buybacks until the NBCUniversal separation.
  • Corrections recorded this edition. Vylor’s first close; Gentherm’s final terms; MSG Rangers’ pro-forma loss; Midera’s net debt; Millrose’s land-bank description; Mobility Global’s September attribution; Octave’s Day-1 base; Qnity’s indemnity; Versant’s debt; the Amentum “worst structure” claim; J&J’s timing; BD’s analyst-day date. Details in the Disclaimer.

NEW Spinoffs Added to Tracking

ParentSpinCoAnnouncedExpectedStatus
Abbott (ABT)Nutrition (name TBD)Oct 21, 2026By end-2027Classic Spinoff; ≈$8.5B sales; CEO Daniel Salvadori; Goldman / Wachtell advising. Graded B (2.90), provisional.
National Fuel Gas (NFG)Integrated Upstream & GatheringOct 14, 2026 (board approval)H2 CY2027Moved from exploratory: tax-free spin, ≥80.1% distributed; CEO Justin Loweth. Graded B (2.75), provisional.
S&P Global (SPGI)Capital IQ and data businessesOct 27, 2026No timetableStrategic review “including potential separation.” Exploratory; not graded.
Silgan (SLGN)MetalCo (JV with AIP)Oct 17, 2026Option only, ≥2 years after closing60/40 JV with ≈$2.26B to Silgan; Silgan may later spin MetalCo or the rest tax-free. Exploratory.
Pineapple Financial (PAPL)Mortgage brokerageOct 9, 2026TBDMicro-cap footnote. Non-binding term sheet mentions a “potential subsequent spin-off”.

Removed / Status Changed

  • ✅ Completed: MSG Rangers (Oct 26), MiniMed full exit (Oct 15), Vylor and Gentherm/Modine (Oct 1), Toro → AI OKTO (Oct 8, micro-cap).
  • ⬆️ KDP → Global Coffee: B (2.95) → B+ (3.15) on the CEO appointment.
  • ⬇️ International Paper → DS Smith plc (EMEA): B → B-: sale talks confirmed, EMEA loss-making, guidance withdrawn.
  • 🆕 Graded: Abbott Nutrition B (2.90); NFG → IUG B (2.75); Eaton → Mobility/Dana first score B (2.90).
  • ⚠️ J&J → DePuy Synthes: the 10-Q (October 21) now says mid-2027 (correction from H2 2027). The CFO says a spin is “currently” preferred. Reported Smith & Nephew combination talks collapsed (FT, October 23); no Apollo deal.
  • ⚠️ Solventum → HIS: Axios reported initial bids at $5.5–7B (October 9); leaning toward a sale (secondary).
  • ⚠️ Textron → Industrial: the 10-Q still lists “several paths”; press reports lean to a sale (secondary).
  • ⚠️ Barrick → North American Barrick: no F-1 filed through October 30, and no SEC filing at all since August. Moved from Q4 2026 to Q1 2027.
  • Removed: Jet.AI → DCTR (the LOI’s 90-day window lapsed with no definitive agreement and no filing since August 14); Click Holdings → Logistics (the October 22 20-F does not mention a spin).
  • Non-US monitored: UPM → WISA effective October 31 (post-pricing), first trade November 2. thyssenkrupp → tk accelis completed October 28 (49% distributed). Informa → Taylor & Francis sale-or-spin opened October 6. Liberty Global → Ziggo (mid-2027) added to the monitored list.

Part 1: Upcoming Spinoffs Overview (Next 12 Months)

IMMEDIATE OPPORTUNITIES (Next 30 Days)

No distribution is scheduled before November 30. The two gating votes inside the window are below; neither completes a separation.

Company (Ticker)SpinCo NameIndustryExpected DateStatusStructureKey Highlights
Flex (FLEX)Axiom Solutions International (AXM)AI Data-Center Power / CoolingEGM Nov 2 (spin Q1 2027)Definitive proxy Oct 5; Innovation Day Nov 10Classic Spinoff · Retained Stake · Anchor InvestorThree-quarters vote on the capital reduction and a bonus issue; $2.0B preferred at $37.5B EV
Unilever (UL)Foods → McCormick RMTFood / SpicesCMA Phase 1 deadline Nov 11 (close mid-2027)FTC early termination Oct 5 (secondary)RMTThe next regulatory binary

Sort: within bucket, by investment grade (highest first).

Q1 2027 SPINOFFS (Jan–Mar)

Company (Ticker)SpinCo NameIndustryExpected DateStatusStructureRevenueKey Highlights
Genuine Parts (GPC)MotionIndustrial DistributionQ1 2027“On track” (Q3, Oct 20); investor days Dec 8–9Classic Spinoff≈$9BQ3 Industrial EBITDA 13.2% (+60bp); GPC’s CEO to Motion; no Form 10
Flex (FLEX)Axiom (AXM)AI Data-Center Power / CoolingQ1 2027 (Form 10: H1 2027)EGM Nov 2; EPC closed Oct 14Classic Spinoff · Retained Stake · Anchor Investor$6.6B FY26 (segment +54% in Sep qtr)$4.4B EPC debt moves to Axiom less $2.0B preferred; Flex keeps 6–12%
Barrick Mining (B)North American BarrickGold Mining⚠️ Q1 2027 (was YE 2026)No F-1 through Oct 30IPO Carve-Out · Retained Stake≈$5.2B10–15% float; CEO said Sep 29 it may “slide into January”
Keurig Dr Pepper (KDP)Global Coffee CoCoffee / BeverageEarly 2027CEO Russ Torres from Nov 3Classic Spinoff≈$16B⬆️ Experienced outside operator; ≈4.5x net leverage; no Form 10
KBR (KBR)Trinzic (TZIC)Defense/Tech ServicesJan 4, 2027Form 10 (Sep 30), no amendment; investor day Nov 12Classic Spinoff · Retained Stake$5.3B8.4–9.6% standalone margin; $1.78B debt, $1.66B to KBR; KBR may keep 19.9%
Eaton (ETN)Mobility Group + DanaAuto ComponentsEnd of Q1 2027 (S-4: “first four months of 2027”)S-4 filed Oct 19 / amended Oct 30; Dana vote Dec 7RMT$3.1B Mobility (≈$11B combined)Mobility EBITDA 14.4% FY25 → 13.5% 1H26; $1.1B to Eaton; 50.1/49.9

Q2–Q4 2027 SPINOFFS (Approaching / Just Beyond the 12-Month Window)

Company (Ticker)SpinCo NameIndustryExpected DateStatusStructureRevenueKey Highlights
Comcast (CMCSA)NBCUniversal (incl. Sky)Media/Entertainment≈Mid-2027“On track” (Q3, Oct 22); buybacks suspended to separationClassic Spinoff · Retained Stake≈$40B+Content & Experiences Q3 EBITDA +29%; up to 19.9% retained for ≤1 year
Abbott (ABT)Nutrition (NEW)Consumer NutritionBy end-2027Announced Oct 21; no Form 10Classic Spinoff≈$8.5BSimilac, Ensure, Pedialyte; insider CEO; debt and margin undisclosed
National Fuel Gas (NFG)Integrated Upstream & Gathering (NEW)Appalachian Gas E&P / MidstreamH2 CY2027Board approved Oct 14Classic Spinoff · Retained Stake≈69% of NFG adj. EBITDA (Sep reports)≈1.1 Bcf/d, ≈5 Tcf; NFG may keep 19.9%; remaining NFG a pure utility
Unilever (UL)Foods → McCormick RMTFood / SpicesMid-2027CMA Phase 1 to Nov 11RMT≈$45B dealUL holders ≈65% / MKC ≈35%
McKesson (MCK)Medical-Surgical Solutions (Wellverse)Healthcare Dist.H2 2027No October developmentIPO Carve-Out · Anchor Investor$11.4BApollo ≈13%; IPO then spin or split-off
J&J (JNJ)DePuy SynthesOrthopedicsMid-2027 (10-Q)CFO: spin “currently” preferred; Enterprise Business Review Dec 8Classic Spinoff≈$9.3BS&N combination talks collapsed (FT, secondary); no Apollo deal
HF Sinclair (DINO)Lubricants & SpecialtiesLubricants2027Q3: “through the capital markets,” ≥80.1%Classic Spinoff · Retained Stake≈$2.3BParent CEO change Jan 1 (Ledbetter); Q3 Lubricants EBITDA $101M
International Paper (IP)DS Smith plc (EMEA)Packaging⚠️ Q1 2027 or saleSale talks confirmed Oct 15; CMD Nov 3Classic Spinoff · Retained Stake · Dual-Listed≈$8.5B⬇️ Q3 EMEA operating loss $(73)M; $1.38B impairment
L3Harris (LHX)Missile Solutions (MSL)Defense/Missiles⚠️ Mid-2027Preferred valued on an IPO before Dec 31, 2027IPO Carve-Out · Retained Stake · Anchor Investor≈$4.1B (FY26 guide)Q3 book-to-bill 11.8x on a $6.3B THAAD award
Textron (TXT)Industrial (Kautex + TSV)Industrial/MobilityQ2–Q3 2027“Several paths” (10-Q)Classic Spinoff≈$3BQ3 segment margin 5.0%; sale reportedly favored (secondary)
Solventum (SOLV)Health Information SystemsHealth IT≈H2 2027Bids reportedly $5.5–7B (secondary)TBD≈$1.36BSale now more likely than a spin

Sort: within bucket, by investment grade (highest first); ties broken by the Part 2 ranking.

EXPLORATORY / UNCERTAIN TIMING

Company (Ticker)SpinCo NameStatusStructureNotes
Adaptive Biotech (ADPT)Immune MedicinePath due by YE 2026TBDNo October development
Spectrum Brands (SPB)Home & Personal CareConfidential Form 10 on fileClassic Spinoff · Anchor InvestorNo filings since August; Oaktree ≈27.3% of HPC
S&P Global (SPGI)Capital IQ and data businesses (NEW)Strategic review (Oct 27)TBDMostly Kensho Data & Platforms inside Market Intelligence; SPGI keeps RatingsDirect and Enterprise Solutions
Silgan (SLGN)MetalCo (NEW)JV signed Oct 17; outside date Oct 15, 2027TBDA spin is an option, not a plan; ≥2 years after closing without AIP’s consent
Vivani Medical (VANI)Cortigent HoldingsDid not close in October; awaiting “final regulatory approval”TBDMicro-cap footnote.
Pineapple Financial (PAPL)Mortgage brokerage (NEW)Special committee (Oct 9)TBDMicro-cap footnote.

Summary: 19 graded upcoming separations after four completions (MSG Rangers, MiniMed’s full exit, Vylor and Gentherm) and two additions (Abbott Nutrition, National Fuel Gas). November is quiet: no distribution falls before the next edition. The pipeline’s first completion is Trinzic on January 4, followed by a cluster in Q1 2027: Axiom, Motion, Global Coffee, Mobility/Dana and possibly North American Barrick. Largest by revenue: Comcast/NBCUniversal (≈$40B+), KDP Global Coffee (≈$16B), McKesson Med-Surg ($11.4B), Eaton/Dana combined (≈$11B), Motion and Abbott Nutrition (≈$8.5–9B). Highest graded: Comcast → NBCUniversal (B+, 3.40). With Vylor gone, nothing upcoming grades above B+.

The month’s theme is optionality. Five of the nineteen now have a live alternative to the spin:

  • Sale talks confirmed or reported: International Paper, Solventum, Textron.
  • A combination discussed and dropped: J&J.
  • A redemption clock if the spin slips past 2027: Flex/Axiom.

Separately, two of the four separations that completed in October drew a legal or capital-structure complication within days. Vylor got the restraining order; Gentherm’s final terms changed from the September announcement.


Part 2: In-Depth Analysis (Top-Tier & Imminent)

Upcoming Spinoffs — Ranked by Grade

All tracked upcoming separations, ranked by investment grade. Score is the weighted scorecard value (shown for the scored names); ★ is the quick visual tier mapped from grade.

RankParent (Ticker) → SpinCoGradeScore★ExpectedKey Thesis
1Comcast (CMCSA) → NBCUniversalB+3.40★★★½≈Mid-2027Universal parks/studios + Peacock/Sky; Content & Experiences EBITDA +29% in Q3; 19.9% retained-stake overhang
2Genuine Parts (GPC) → MotionB+3.35★★★½Q1 2027#1 North American industrial MRO distributor; parent CEO moves to SpinCo; margin rising
3Flex (FLEX) → Axiom (AXM)B+3.35★★★½Q1 2027+54% segment growth; parent CEO moves to SpinCo; EPC debt and a $2.0B preferred on the cap table
4Barrick (B) → North American BarrickB+3.25★★★½⚠️ Q1 2027Four Tier One gold assets; 10–15% float; no F-1 yet
5Keurig Dr Pepper (KDP) → Global Coffee CoB+3.15★★★½Early 2027≈$16B coffee scale; CEO named (upgraded)
6KBR (KBR) → Trinzic (TZIC)B2.95★★★Jan 4, 20278.4–9.6% standalone margin; $1.66B of its debt to KBR; up to 19.9% retained
7Eaton (ETN) → Mobility Group + DanaB2.90★★★End Q1 2027RMT via exchange offer; Mobility margin falling; $1.1B to Eaton (first score)
8Abbott (ABT) → NutritionB2.90★★★By end-2027Category-leading brands; financials and liabilities undisclosed (NEW)
9National Fuel Gas (NFG) → Integrated Upstream & GatheringB2.75★★★H2 2027Scaled Appalachian gas plus gathering; 19.9% may be retained (NEW)
10Unilever (UL) → Foods → McCormick RMTB—★★★Mid-2027≈$45B; CMA Phase 1 decision due Nov 11
11McKesson (MCK) → Medical-Surgical SolutionsB—★★★H2 2027$11.4B; Apollo 13% minority stake
12J&J (JNJ) → DePuy SynthesB—★★★Mid-2027Spin preferred; alternatives explored and dropped
13HF Sinclair (DINO) → Lubricants & SpecialtiesB—★★★2027≈$2.3B capital-light lubricants
14International Paper (IP) → DS Smith plc (EMEA)B-—★★½⚠️ Q1 2027 or saleLoss-making in Q3; sale talks confirmed (downgraded)
15L3Harris (LHX) → Missile Solutions (MSL)B-—★★½⚠️ Mid-2027IPO deadline embedded in the government preferred
16Textron (TXT) → Industrial (Kautex + TSV)B-—★★½Q2–Q3 2027Sale-or-spin still undecided
17Adaptive Biotech (ADPT) → Immune MedicineB-—★★½YE 2026 pathStructure TBD
18Solventum (SOLV) → Health Information SystemsB-—★★½≈H2 2027Bids reported; sale likelier
19Spectrum Brands (SPB) → Home & Personal CareC+—★★IndefiniteSpin/sale/merger all live

Not ranked: S&P Global → Capital IQ (review), Silgan → MetalCo (option); micro-cap footnotes Vivani → Cortigent and Pineapple Financial. Non-US monitored only: UPM → WISA, Tamarack/Headwater → Tributary, Informa → Taylor & Francis, Liberty Global → Ziggo.

Sort: by investment grade / weighted score, highest first. Ties broken by revenue (Motion ≈$9B ahead of Axiom $6.6B; Mobility/Dana ≈$11B combined ahead of Abbott Nutrition ≈$8.5B). Removed this edition: MSG Rangers, MiniMed full exit, Vylor, Gentherm/Modine (completed); Jet.AI, Click Holdings (lapsed).

Deep-dive roster note: the nine deep-dives below are the six highest-graded upcoming names plus three promoted on new primary filings:

  • Eaton/Dana: its S-4 carries the first standalone financials.
  • Abbott Nutrition: new announcement.
  • National Fuel Gas: board decision.

Comcast’s, Motion’s, Barrick’s and Trinzic’s sections are short; none filed anything that moves a dimension. Deep-dives run in ranked order.


1. Comcast → NBCUniversal

Executive Summary

  • Company: Comcast Corporation (CMCSA) — Price: $23.22 (Oct 30, 2026), +6.7% in October
  • SpinCo: NBCUniversal (including Sky) — Expected Completion: ≈Mid-2027
  • Structure: Classic Spinoff · Retained Stake — Investment Grade: B+ (Solid Opportunity)

Key Developments Since Last Report

  • Q3 (October 22):
    • Content & Experiences revenue $10,537M (+6.5%), adjusted EBITDA $1,800M (+29%). Peacock adjusted EBITDA $261M on 48M subscribers. Theme parks face “near-term cyclical headwinds”.
    • The separation is “on track”.
    • Share buybacks are suspended until the separation.
  • Connectivity, the RemainCo, lost 144K domestic broadband customers; broadband revenue fell 4.7%.
  • The 10-Q repeats the up-to-19.9% retained stake for up to one year.
  • No public Form 10, name or ticker.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%4Content & Experiences EBITDA +29% in Q3; Peacock profitable ($261M)
Competitive Position25%4Universal IP, top-tier theme parks, Sky footprint
Strategic Rationale20%3Clean thesis, but the up-to-19.9% retained stake defers full separation
Management & Governance20%3Cavanagh named; Form 10 pending
Acquisition Potential10%2Too large for most acquirers
Weighted Score3.40
Investment GradeB+Solid Opportunity

Grade Change: B+ (3.40) maintained. The segment print supports Financial Profile at 4. The buyback suspension tells us where Comcast is putting its capital: towards completing the separation.

Recommendation: ⭐⭐⭐ MONITOR. About eight months out with no Form 10. The retained stake remains the single change that would move the score.

Sources


2. Genuine Parts → Motion

Executive Summary

  • Company: Genuine Parts Company (GPC) — Price: $120.90 (Oct 30, 2026), −3.8% in October
  • SpinCo: Motion — industrial MRO and bearings/power-transmission distribution; RemainCo GPC (NAPA, global automotive)
  • Expected Completion: Q1 2027 — Structure: Classic Spinoff — Investment Grade: B+ (Solid Opportunity)

Key Developments Since Last Report

  • Q3 (October 20): the Industrial segment posted sales of $2.4B (+6.1%, comparable +5.5%) and segment EBITDA of $317M, a 13.2% margin, up 60bp. Separation “on track” for Q1 2027; GPC narrowed adjusted EPS guidance to $7.50–7.75.
  • GPC filed a routine debt shelf (S-3ASR, October 16). No Form 10. The Q3 release does not mention the December 8–9 investor days.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%3≈$9B revenue at a 13.2% Q3 segment EBITDA margin, improving; ⚠️ separation debt and share count undisclosed
Competitive Position25%4#1 North American industrial MRO/bearings distributor
Strategic Rationale20%3Two unrelated distribution models; value depends on Motion re-rating to industrial-distributor multiples
Management & Governance20%4Parent CEO Will Stengel moves to Motion; full C-suite named
Acquisition Potential10%2Few buyers at this scale; §355(e)
Weighted Score3.35
Investment GradeB+Solid Opportunity

Grade Change: B+ (3.35) maintained, provisional on the Form 10. A segment margin is not a standalone margin; the Trinzic lesson (Part 2 §6) is that standalone corporate cost takes 1.5–3 points off. Financial Profile stays at 3 until the information statement sets the debt.

Recommendation: ⭐⭐⭐ ACCUMULATE GPC ahead of the Form 10 and investor days.

Sources


3. Flex → Axiom Solutions International (AXM)

Executive Summary

  • Company: Flex Ltd. (FLEX) — Price: $86.48 (Oct 30, 2026), −21.4% in October
  • SpinCo: Axiom Solutions International, Inc. (Nasdaq: AXM) — power and cooling infrastructure for AI data centers and the grid, now including EPC Power
  • Expected Completion: Q1 2027 (the Form 10 says “first half of calendar 2027”)
  • Structure: Classic Spinoff · Retained Stake · Anchor Investor — Investment Grade: B+ (Solid Opportunity)
  • Key Thesis: October filled in Axiom’s capital structure before it trades. EPC Power is bought and its debt assigned to Axiom. A third-party preferred holder now ranks ahead of the common. The growth is accelerating, and the parent’s CEO and CFO are still moving across.

Key Developments Since Last Report

$2.0B convertible preferred (agreement October 2; 8-K October 5):

  • Buyers: General Catalyst, Koch Equity Development and co-investors, at an implied initial Axiom enterprise value of $37.5B.
  • Dividend: 10% cash before the spin, then 6% cash or 7% paid-in-kind.
  • One board seat for General Catalyst.
  • If the spin has not happened by December 31, 2027, Axiom must redeem at 115% in cash or 125% in Flex shares, and Flex guarantees the redemption.
  • After the spin, Axiom cannot pay common dividends or buy back stock unless the preferred is current and net leverage is ≤4x. Debt that takes leverage above 4x needs the holders’ consent.

EPC Power closed October 14:

  • $4.4B cash, funded with a $3.3B 364-day term loan and a $1.1B bridge, both due October 13, 2027.
  • The 10-Q (October 30) says the $4.4B of EPC debt transfers to Axiom at the spin, reduced by the preferred proceeds. That leaves Axiom with ≈$2.4B of debt plus the $2.0B preferred (the report’s arithmetic from the 10-Q). Flex is repaid through the “SpinCo Cash Distribution”.

Q2 FY27 (October 28):

  • The Cloud & Power segment reported sales $2,508M, +54%, and operating income $268M (10.7% vs 8.3%).
  • First half: $4,710M of sales at a 10.2% margin.
  • FY27 segment guidance is +75–85% sales at an 11.5–11.7% adjusted operating margin including EPC.
  • Spin costs were $144M in the half.
  • Standalone EBITDA is still undisclosed.

Mechanics and votes:

  • The definitive proxy (October 5) puts the capital reduction and a bonus issuance (capitalizing up to $5.5B of reserves) to the November 2 EGM.
  • Distribution 88–94%; ratio and record date blank.
  • Amazon’s Flex warrant was converted to a penny-strike Axiom warrant (October 9).
  • An October 23 proxy supplement adds 25-year Guadalajara lease and site-services agreements.

The October decline (FLEX −21.4%) came alongside Modine (−30.7%) and Eaton (−13.9%). That points to a de-rating of the data-center power and cooling group, not to anything Axiom-specific.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%3+54% segment growth at a 10.7% and rising operating margin; ≈$2.4B of debt plus a $2.0B senior preferred; standalone EBITDA undisclosed ⚠️ provisional
Competitive Position25%4Scaled data-center power and liquid-cooling position; EPC adds grid-scale power conversion
Strategic Rationale20%3Clear multiple unlock; marked down for the retained 6–12%, the parent-set acquisition and the preferred’s dividend blocker on the common
Management & Governance20%4Flex’s sitting CEO and CFO move to Axiom; full board; a sophisticated outside holder now on it
Acquisition Potential10%2$37.5B EV and §355(e)
Weighted Score3.35
Investment GradeB+Solid Opportunity

Grade Change: B+ (3.35) maintained, provisional. The preferred substitutes ≈$2B of senior equity for ≈$2B of debt. That is better for solvency, but no better for common holders’ claim on cash flow; the dimension holds at 3. What would move it: the amended Form 10’s standalone EBITDA, and whether net leverage on it sits under the preferred’s 4x blocker.

Recommendation: ⭐⭐⭐ ACCUMULATE FLEX into the record date, unchanged, with the November 2 EGM as the gate and the November 10 Innovation Day as the first standalone-economics disclosure. The October fall improves the entry; it was a sector move.

Sources


4. Barrick → North American Barrick

Executive Summary

  • Company: Barrick Mining Corporation (B) — Price: $37.01 (Oct 30, 2026), −9.0% in October
  • SpinCo: North American Barrick — Nevada Gold Mines (Carlin, Cortez, Turquoise Ridge) plus Pueblo Viejo
  • Expected: ⚠️ Q1 2027 (moved from year-end 2026) — Structure: IPO Carve-Out · Retained Stake — Investment Grade: B+

Key Developments Since Last Report

  • No October development found. Barrick has filed nothing with the SEC since August: no F-1, no S-1, no 6-K on the IPO. The only timing evidence is still the CEO’s September 29 “may slide into January”.
  • Why the bucket moves: a year-end pricing would need a public registration statement in November and a December roadshow. With no filing on October 30, the report moves the expected date to Q1 2027. This is the report’s inference, not company guidance.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%4≈$5.2B revenue from four Tier One assets; ⚠️ no standalone financials filed
Competitive Position25%3Tier One orebodies, but a price-taking commodity
Strategic Rationale20%4Newmont settlement made the plan executable
Management & Governance20%3CEO Mark Hill named; comp undisclosed
Acquisition Potential10%185–90% retained — not acquirable
Weighted Score3.25
Investment GradeB+Solid Opportunity

Grade Change: B+ (3.25) maintained. Last edition set “a second slip, or no F-1 by November” as the red-flag test. The second half of that test now runs out within weeks; December’s edition downgrades Strategic Rationale if there is still no filing.

Recommendation: ⭐⭐⭐ OWN THE PARENT, NOT THE FLOAT — unchanged.

Sources


5. Keurig Dr Pepper → Global Coffee Co — ⬆️ Upgraded on the CEO appointment

Executive Summary

  • Company: Keurig Dr Pepper (KDP) — Price: $35.84 (Oct 30, 2026), +18.1% in October
  • SpinCo: Global Coffee Co — Keurig single-serve plus JDE Peet’s (≈$16B of sales); RemainCo Beverage Co (CEO Tim Cofer)
  • Expected Completion: early 2027 — Structure: Classic Spinoff — Investment Grade: B+ (Solid Opportunity) ⬆️ (from B)
  • Key Thesis: The three-month leadership gap that drove July’s downgrade is closed, by an operator from a larger consumer company rather than an internal stopgap.

Key Developments Since Last Report

  • October 1 (8-K): Russ Torres, President & COO of Kimberly-Clark, named CEO of Global Coffee Co, joining November 3. Until separation he runs the Coffee unit and the JDE Peet’s integration, reporting to Cofer; Pamela Patsley will chair the SpinCo.
  • Separation still “targeted for early 2027”. No Form 10, no CFO named and no compensation disclosed. No Q3 release on EDGAR by October 30.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%3≈$16B scale but leveraged (≈4.5x) post-JDE Peet’s
Competitive Position25%4Genuine global coffee scale (Keurig + JDE Peet’s)
Strategic Rationale20%3Focus-unlock is real; integration and timing risk persist
Management & Governance20%3 ⬆️Experienced external CEO named; CFO, board and compensation still undisclosed (was 2)
Acquisition Potential10%2Too large and too levered for most acquirers
Weighted Score3.15
Investment GradeB+Solid Opportunity

Grade Change: Upgraded B (2.95) → B+ (3.15). Trigger: the October 1 8-K. The methodology scores “CEO named but unproven, compensation not yet disclosed” at 3. A 4 needs most key roles filled and meaningful equity grants, which the Form 10 will show. This partly reverses July’s B+ (3.35) → B downgrade; the remaining 0.2 is the gap between a named CEO and a full disclosed team.

Recommendation: ⭐⭐⭐ HOLD KDP. The stock rose 18.1% in October; the appointment is priced. The Form 10 decides the leverage question, which is still the weakest dimension.

Sources


6. KBR → Trinzic (TZIC)

Executive Summary

  • Company: KBR, Inc. (KBR) — Price: $38.70 (Oct 30, 2026), +10.1% in October
  • SpinCo: Trinzic, Inc. (NYSE: TZIC) — Mission Technology Solutions
  • Expected Completion: January 4, 2027 — Structure: Classic Spinoff · Retained Stake — Investment Grade: B (Moderate / Hold)

Key Developments Since Last Report

  • Q3 (October 29):
    • The MTS segment reported revenue of $1,266M (−4.5%, lower NASA work) and adjusted EBITDA of $145M (11.5%). Year to date: $3,870M at 11.4%.
    • These are segment figures. The Form 10’s standalone margins are 8.4% (FY25) and 9.6% (1H26). The report scores the standalone.
    • Backlog fell to $11.9B from $12.6B.
  • Investor days: KBR November 11, Trinzic November 12.
  • No Form 10 amendment and no update to the retained-stake disposal plan. The January 4 target still requires effectiveness.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%28.4–9.6% standalone margin; $1,780M debt (≈3.6–4.0x), $1,664M of it paid to KBR; revenue now declining and backlog down
Competitive Position25%3Defense/space services scale in a recompete-driven market
Strategic Rationale20%3Parent keeps up to 19.9% and takes 93% of the debt raised
Management & Governance20%4External CEO (LaRouche) and CFO (Veasey) named; firm date
Acquisition Potential10%3Federal services consolidates; §355(e) and any retained stake delay it
Weighted Score2.95
Investment GradeBModerate / Hold

Grade Change: B (2.95) maintained. A 4.5% segment revenue decline with backlog down 6% is a negative for Financial Profile, which is already at 2.

Recommendation: ⭐⭐⭐ HOLD KBR; do not buy for the distribution. The November 12 investor day is the next disclosure; read it for the standalone 2027 margin and the disposal plan for the 19.9%.

Sources


7. Eaton → Mobility Group + Dana (RMT) — first score on the S-4 (promoted on new filing)

Executive Summary

  • Companies: Eaton (ETN) $369.97, −13.9% in October · Dana (DAN) $23.11, −15.4%
  • SpinCo: Mobility (USA) Corp, Eaton’s vehicle and eMobility components business, merging into Dana on day one
  • Expected Completion: “around the end of Q1 2027” (Dana); the S-4 says “first four months of 2027”
  • Structure: RMT — Investment Grade: B (Moderate / Hold) (first score)
  • Key Thesis: The registration statement shows a business shrinking and losing margin before it leaves. Eaton takes $1.1B of cash and exits automotive; Eaton holders who tender get half of a combined Dana.

What the S-4 (October 19; Amendment No. 1 October 30) discloses

ItemFigure
Mobility net salesFY2025 $3,140M (−10%; −11% organic); FY2024 $3,481M; 1H26 $1,620M
Mobility adjusted EBITDAFY2025 $451M (14.4%); FY2024 $564M (16.2%); 1H26 $219M (13.5%)
FY2025 net income$175M
Cash to Eaton$1.1B before adjustments
Financing$2.6B bridge, reduced by a $350M Term Loan A
Ownership of combined DanaEaton holders 50.1% / Dana holders 49.9%
Separation mechanicsExchange offer by redemption of Eaton shares, at a discount left blank; clean-up spin if undersubscribed
Accounting acquirerDana, which keeps its name and ticker
Dana termination fee$158.7M

Dana’s Q3 call (Rule 425, October 28) added:

  • A special meeting on December 7.
  • “All regulatory approvals received but one”.
  • Pro-forma net leverage of 1.6x and $250M of synergies.
  • Pre-close buybacks raised to $469M for 2026. Post-close buybacks need Eaton’s agreement under the tax rules.

Reading it: margin has fallen 2.7 points in eighteen months on volume declines. The $1.1B to Eaton is ≈2.4x FY25 EBITDA and is funded by the SpinCo’s own borrowing. The combined company’s 1.6x leverage is moderate because Dana’s balance sheet absorbs it.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%314.4% → 13.5% EBITDA margin on −10% sales; $1.1B to Eaton from SpinCo debt; combined 1.6x net leverage
Competitive Position25%3Scaled drivetrain and e-mobility components, combined with Dana’s axles; cyclical, price-pressured OEM tier
Strategic Rationale20%3Eaton exits a non-core auto business at 8.3x pro-forma EBITDA; the combination’s $250M of synergies is the holders’ upside
Management & Governance20%3Dana management runs the combination; Eaton holders get half the equity but not control
Acquisition Potential10%2A ≈$11B auto supplier with §355(e) constraints
Weighted Score2.90
Investment GradeBModerate / Hold

Grade Change: B (unscored) → B (2.90), first score. The trigger is the S-4, the first primary disclosure of Mobility’s standalone numbers. The letter is unchanged.

Recommendation: ⭐⭐⭐ HOLD ETN; evaluate the exchange offer on its discount when the ratio is set. For Eaton holders this is a split-off: tender only if the discount compensates for swapping Eaton for half of a shrinking auto supplier. Dana holders vote December 7.

Sources


8. Abbott → Nutrition — 🆕 NEW (promoted on new announcement)

Executive Summary

  • Company: Abbott Laboratories (ABT)
  • SpinCo: Abbott’s Nutrition business (name and ticker TBD). Pediatric (Similac, PediaSure, Pedialyte) and adult (Ensure, Glucerna) nutrition; ≈16,000 employees and 14 plants
  • RemainCo: Abbott, with ≈$42B of sales across medical devices, diagnostics and established pharmaceuticals
  • Expected Completion: by end-2027, subject to a Form 10, regulatory approvals and final board approval
  • Structure: Classic Spinoff — Investment Grade: B (Moderate / Hold) (first grade, provisional)

Transaction Overview

  • Announced October 21, 2026 (8-K Ex. 99.1). Tax-free pro-rata distribution; no retained stake disclosed. Abbott says the two companies’ combined dividend will equal Abbott’s current dividend.
  • CEO: Daniel Salvadori, Abbott EVP and Group President, Established Pharma & Nutrition, an insider.
  • Advisors: Goldman Sachs and Wachtell Lipton.
  • Not disclosed: segment EBITDA, separation debt, the allocation of litigation liabilities, board.

What the filing will have to answer: which entity carries the necrotizing-enterocolitis (NEC) infant-formula litigation is a question for the Form 10. This report has not seen the allocation and does not score it. It is the Strategic Rationale input to watch.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%2≈$8.5B of sales; margin, debt and share count undisclosed — scored on the missing-data default
Competitive Position25%4Category-leading brands in US infant formula and adult nutrition
Strategic Rationale20%3Separates a slower-growing consumer business from devices; liability allocation unknown
Management & Governance20%3Insider CEO named; rest of team and comp undisclosed
Acquisition Potential10%2Infant-formula concentration draws antitrust scrutiny; §355(e)
Weighted Score2.90
Investment GradeBModerate / Hold

Grade Change: First grade, provisional on a press release and 8-K. Two dimensions sit on the missing-data default; the Form 10 will move them in either direction.

Recommendation: ⭐⭐⭐ MONITOR. More than a year from distribution.

Sources


9. National Fuel Gas → Integrated Upstream & Gathering — 🆕 NEW (promoted on board decision)

Executive Summary

  • Company: National Fuel Gas Company (NFG) — Price: $79.55 (Oct 30, 2026), +4.9% in October
  • SpinCo: Integrated Upstream & Gathering (IUG) — Seneca Resources plus the gathering business: ≈1.1 Bcf/d of net production, ≈1.2M net acres, ≈5 Tcf of proved reserves
  • RemainCo: National Fuel, a 100% regulated utility and pipeline company with nearly $5B of rate base after closing its Ohio utility acquisition on October 1
  • Expected Completion: H2 calendar 2027 — Structure: Classic Spinoff · Retained Stake — Investment Grade: B (Moderate / Hold) (first grade, provisional)

Transaction Overview

  • Board approval October 14 (8-K) of a tax-free spin, following the strategic review this report added in September. Sale and merger were the alternatives considered.
  • NFG distributes at least 80.1% and may retain up to 19.9%, to be disposed of tax-efficiently.
  • CEO: Justin Loweth, current President of Seneca and the midstream business.
  • Not disclosed: IUG debt, EBITDA, share count. FY27 guidance comes in November.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%2Scale is disclosed; margin, debt and cash to parent are not — missing-data default
Competitive Position25%3Low-cost Appalachian position with integrated gathering; a commodity price-taker
Strategic Rationale20%3Clean regulated/E&P separation; marked down for the possible 19.9% retained stake
Management & Governance20%3Insider CEO named; team and comp undisclosed
Acquisition Potential10%3Appalachian gas is consolidating, but §355(e) and any retained stake delay it
Weighted Score2.75
Investment GradeBModerate / Hold

Grade Change: First grade, provisional. Last edition carried NFG as an ungraded strategic review on secondary sources; the 8-K is the first primary document.

Recommendation: ⭐⭐⭐ MONITOR.

Sources


Part 2B: BRIEF UPDATES — OTHER TRACKED UPCOMING SPINOFFS

  • Unilever → Foods/McCormick RMT:
    • The FTC granted early termination of the HSR waiting period on October 5 (secondary, FoodNavigator).
    • The CMA Phase 1 decision is due November 11.
    • Unilever’s Q3 (October 28; underlying sales growth 5.2%) calls the deal “on track”. McCormick has no S-4 on file. No buyer for Colman’s.
    • (B maintained.)
  • McKesson → Medical-Surgical Solutions (Wellverse): no October development. The October 6 8-K is an unrelated co-investment with CD&R in Option Care Health. (B maintained.)
  • J&J → DePuy Synthes:
    • The 10-Q (October 21) says the separation is expected in mid-2027; the report carried H2 2027.
    • On the Q3 call the CFO said J&J is leaning toward a spin, with pro formas likely at the December 8 Enterprise Business Review (secondary transcript).
    • The FT reported on October 23 that talks to combine DePuy with Smith & Nephew (≈$34B, J&J holders 50.1%) collapsed over the CEO role (secondary). No Apollo deal.
    • (B maintained. The “at risk of conversion to a sale” flag is lowered but not removed.)
  • HF Sinclair → Lubricants & Specialties:
    • Q3 Lubricants adjusted EBITDA $101M (vs $114M). The 10-Q describes the separation as “through the capital markets,” distributing at least 80.1%, substantially completed over 2027; the report labels it Retained Stake on that language.
    • The Mississauga base-oil refinery retires in H2 2027.
    • Parent CEO change: Steve Ledbetter becomes CEO January 1, 2027, with Franklin Myers Executive Chair until the separation completes.
    • On October 30, HF Sinclair agreed to buy back 2.35M shares (≈$257M) from REH.
    • (B maintained.)
  • International Paper → DS Smith plc (EMEA):
    • The SpinCo is named DS Smith plc (LSE listing plus a Level II NYSE ADR; CEO Tim Nicholls, CFO Vincent Bonnot); Capital Markets Day November 3.
    • On October 15 IP confirmed preliminary sale talks after unsolicited approaches (FT names Lone Star and Atlas, with bids reportedly below $6B; secondary).
    • The Q3 10-Q shows EMEA at a $(73)M operating loss and a $1.38B non-cash goodwill impairment. IP has stopped giving EMEA guidance, citing UK listing rules.
    • ⬇️ Downgraded B → B- on primary disclosure: a loss-making SpinCo, an impairment that resets what the parent thinks the business is worth, and a live sale path.
  • Medtronic → MiniMed full exit: ✅ completed October 15; covered in Part 3.
  • L3Harris → Missile Solutions:
    • Q3 segment revenue $1,057M (+5%), book-to-bill 11.8x on a $6.3B THAAD propulsion award; FY ≈$4.1B.
    • The 10-Q values the Department of War’s preferred assuming a qualified IPO before December 31, 2027. The IPO date is no longer open-ended.
    • (B- maintained.)
  • Textron → Industrial: Q3 Industrial revenue $765M (+1%) at a 5.0% segment margin. The 10-Q still lists “several paths,” 12–18 months from announcement. A sale is reportedly favored (24/7 Wall St., secondary). (B- maintained.)
  • Adaptive Biotechnologies → Immune Medicine: no October development; the path is due by year-end. (B- maintained.)
  • Solventum → Health Information Systems: no filings since September; Axios reported first-round bids valuing HIS at $5.5–7B (October 9; secondary). Q3 November 5. (B- maintained; likely to leave the tracker as a sale.)
  • Spectrum Brands → Home & Personal Care: no filings since August. (C+ maintained.)
  • Micro-caps: Vivani → Cortigent — the October 30 8-K says the ClearOne merger did not close in October and awaits final regulatory approval. Pineapple Financial (NEW) — special committee formed October 9. Jet.AI and Click Holdings removed (above). Footnotes only.
  • Non-US monitored:
    • UPM → WISA — demerger effective October 31 (post-pricing), first trade November 2, 1 WISA per UPM.
    • thyssenkrupp → tk accelis — completed October 28, 49% distributed.
    • Informa → Taylor & Francis — sale or spin to be decided by March 2027.
    • Stora Enso → Bergslagets Skogar — H1 2027.
    • Liberty Global → Ziggo — mid-2027 (added).
    • NGEx → Valiente; China Travel → CTG HK & Macao (≈November 26).
    • Tamarack/Headwater → Tributary — mid-Q4.
    • ABF → Primark — December 2027.

Part 3: COMPLETED SPINOFFS — Extended Post-Spinoff Analysis

All prices as of October 30, 2026 close (verified daily data via yfinance and the site’s nightly series). SpinCo returns vs the Day-1 reference basis fixed in prior reports (open or close as noted per name); post-spin low = lowest closing price since the first regular-way trading day. Returns are price returns and exclude dividends.

COMPLETED SPINOFFS SUMMARY TABLES

Table A: Overview & Ratings

TickerParentSpinCoSpinoff DateStatusSpinCo % Since SpinoffParent % Since SpinoffStructureRating
MSGRMSGS → MSGKMSG RangersOct 26, 2026NYSE+23.0%MSGK +2.4%Classic Spinoff · Dual-Class⭐⭐⭐ B — NOT RATED (NEW)
VYLRCTVAVylorOct 1, 2026NYSE+6.1%CTVA −7.4%Classic Spinoff⭐⭐⭐ A- — SELL (NEW)
THRMMODGentherm (Modine Performance Technologies RMT)Oct 1, 2026Nasdaq−8.0%MOD −31.4%RMT⭐⭐⭐ B+ — HOLD (NEW; no valuation)
ADIGREZIADI Global DistributionAug 3-4, 2026NYSE−20.5%REZI −28.4%Classic Spinoff⭐⭐⭐ B — HOLD
MFPMIDDMidera Food ProcessingJul 7, 2026Nasdaq+9.6%MIDD −14.6%Classic Spinoff⭐⭐⭐ B+ — TRIM ⬇️
MBGLSPGIMobility GlobalJul 1, 2026NYSE (S&P SmallCap 600)−10.8%SPGI +12.4%Classic Spinoff⭐⭐⭐⭐ A — BUY
HONAHONHoneywell AerospaceJun 29, 2026Nasdaq−30.0%HON −4.2%Classic Spinoff · Multi-Way⭐⭐⭐ B+ — ACCUMULATE ⬇️
FDXFFDXFedEx FreightJun 1, 2026NYSE−15.7%FDX −7.4%Classic Spinoff · Retained Stake⭐⭐⭐ B+ — TRIM ⬇️
NVRIEnviriNew EnviriJun 1-2, 2026NYSE−4.1% (+$15/sh cash)Parent absorbedClassic Spinoff · Taxable · Paired Sale⭐⭐⭐ B — HOLD (legacy)
OCTVHXGBFOctave IntelligenceMay 28, 2026Nasdaq NY + STO SDR+27.3% (Day-1 base corrected)Hexagon +17.8%Classic Spinoff · Dual-Listed⭐⭐⭐ B — TRIM ⬇️
CHRNAPLDChronoScaleMay 5, 2026Nasdaq+8.8%APLD −55.3%RMT⚠️ NOT RATED
TRAXANABFirst Tracks BioApr 20, 2026Nasdaq+142.4%ANAB −5.2%Classic Spinoff⚠️ NOT RATED
VGNTAPTVVersigentApr 1, 2026NYSE+47.4%APTV −43.5%Classic Spinoff⭐⭐⭐⭐ B+ — ACCUMULATE ⬇️
JANDOCJanus LivingMar 20, 2026NYSE REIT+20.8% (+42.6% vs IPO)DOC −4.8% (vs IPO ref)IPO Carve-Out · REIT⭐⭐⭐ BUY (legacy)
MMEDMDTMiniMedMar 6, 2026Nasdaq−4.0% (−8.6% vs IPO)MDT +3.3%IPO Carve-Out⚠️ NOT RATED
RNARNAAtrium TherapeuticsFeb 26, 2026Nasdaq−43.9%Acquired by NovartisPre-Acquisition Spin⚠️ NOT RATED
WATBDXBD Biosciences RMTFeb 9, 2026CombinedN/A (RMT)BDX +21.4%RMT⭐⭐ HOLD (legacy)
VSNTCMCSAVersantJan 5, 2026Nasdaq−30.4%CMCSA −16.5%Classic Spinoff · Dual-Class⭐⭐⭐ B — ACCUMULATE
MICCULMagnum Ice Cream CoDec 6, 2025NYSE/Euronext/LSE+33.4%UL +5.6%Classic Spinoff⭐⭐⭐⭐ A- — HOLD (first grade)
QDDQnityNov 3, 2025S&P 500+11.1%DD +35.8%‡Classic Spinoff⭐⭐⭐ A- — HOLD
SOLSHONSolsticeOct 30, 2025S&P MidCap 400 (corrected)+21.0%n/m†Classic Spinoff⭐⭐⭐ A- — HOLD
RALFTVRalliantJun 30, 2025NYSE+38.6%FTV +25.1%Classic Spinoff⭐⭐⭐ A- — TRIM ⬇️
STRZLGFStarzMay 7, 2025Nasdaq+97.2%N/A (parent split)Parent Split⭐⭐⭐ HOLD (legacy)
LIONLGFLionsgate StudiosMay 7, 2025Nasdaq+52.8%N/A (parent split)Parent Split⭐⭐⭐⭐ BUY (legacy)
SNDKWDCSandiskFeb 24, 2025Nasdaq+2,268.1%WDC +646.9%Classic Spinoff⭐⭐ B — TRIM ⬇️
MRPLENMillrose PropertiesFeb 7, 2025NYSE REIT+9.1%LEN −27.4%Classic Spinoff · REIT⭐⭐⭐ B — HOLD ⬇️ (on watch; first grade)
ECGMDUEverus ConstructionNov 1, 2024NYSE+95.5%MDU +30.6%Classic Spinoff⭐⭐⭐ B+ — HOLD
SOBOTRPSouth BowOct 2, 2024NYSE / TSX+52.7%TRP +46.5%Classic Spinoff⭐⭐⭐ B — HOLD
AMTMJAmentumSep 30, 2024NYSE−32.2%J +19.3%§RMT · Retained Stake⭐⭐⭐ B — ACCUMULATE ⬇️

Sort: by spinoff date, most recent first. All SpinCo returns are vs the Day-1 reference unless noted; parent baselines are each parent’s first regular-way (ex-distribution) close. Added this edition: MSGR, VYLR and THRM. THRM is the combined Gentherm after the RMT, measured from its October 1 close; like WAT, it has no separate SpinCo security. ⬇️/⬆️ mark rating changes this edition; several follow the move to the five-band scale rather than any change in the business (per-name notes). (legacy) = a rating carried from before the scale, with no target, until a profile values the name.

† Honeywell’s pre-breakup comparison remains n/m (3-way breakup + reverse split). ‡ DuPont split-adjusted for its 1-for-3 reverse split; raw quote $140.05. § Jacobs on the provider-adjusted series (1.010 factor, May 16, 2025). CTVA and MSGK carry provider rescales (6.665 on October 1; 1.328 on October 27), so their pre-spin history in adjusted series is divided by those factors; their parent returns here run from the first regular-way close after the spin ($12.57 and $305.42), never across the rescale.

Table B: SpinCo Price Performance & Post-Spin Low Recovery (Updated October 30, 2026)

TickerDay 1 PricePost-Spin Low (close)Low DateDays to LowCurrent (Oct 30)vs Day 1vs Low
MSGR$177.61 (close, Oct 27)$177.61Oct 27, 20260$218.49+23.0%+23.0%
VYLR$68.26 (close, Oct 1)$67.26Oct 2, 20261$72.40+6.1%+7.6%
THRM$33.63 (close, Oct 1)$26.15Oct 22, 202621$30.95−8.0%+18.4%
ADIG$22.00 (close, Aug 4)$15.22Oct 19, 202676$17.48−20.5%+14.8%
MFP$36.60 (close)$36.60Jul 7, 20260$40.12+9.6%+9.6%
MBGL$21.19 (close)$17.15Sep 30, 202691$18.91−10.8%+10.3%
HONA$220.19 (close)$151.58Sep 9, 202672$154.15−30.0%+1.7%
FDXF$149.53 (close)$107.95Oct 21, 2026142$126.04−15.7%+16.8%
NVRI$19.20 (close, Jun 2)$17.75Jun 3, 20261$18.42−4.1%+3.8%
OCTV$17.05 (close, May 28) (corrected)$15.50Jul 23, 202656$21.71+27.3%+40.1%
CHRN$13.22 (close)$13.22May 5, 20260$14.38+8.8%+8.8%
TRAX$18.60 (close)$15.32Jun 3, 202644$45.08+142.4%+194.3%
VGNT$27.85 (close)$26.94Apr 7, 20266$41.06+47.4%+52.4%
JAN$23.60 (close)$22.88Mar 27, 20267$28.52+20.8% (+42.6% vs IPO)+24.7%
MMED$19.05 (open)$10.80May 15, 202670$18.28−4.0% (−8.6% vs IPO)+69.3%
RNA≈$14.75 (open)$7.61Oct 19, 2026235$8.27−43.9%+8.7%
VSNT$45.17 (open)$27.42Feb 12, 202638$31.42−30.4%+14.6%
MICC$14.90 (open)$13.06Apr 29, 2026141$19.87+33.4%+52.1%
Q$105.01 (open)$73.54Nov 24, 202521$116.67+11.1%+58.6%
SOLS$50.05 (open)$41.43Nov 18, 202519$60.55+21.0%+46.2%
RAL$48.49 (close)$38.39Feb 5, 2026220$67.21+38.6%+75.1%
STRZ$11.20 (close)$8.65Feb 5, 2026274$22.09+97.2%+155.4%
LION$8.15 (close)$5.59Jul 7, 202561$12.45+52.8%+122.7%
SNDK$48.60 (close)$29.62Apr 22, 202557$1,150.89+2,268.1%+3,785.5%
MRP$23.49 (open)$21.22 ¶Mar 11, 202531$25.62+9.1%+20.7%
ECG$52.49 (close, Nov 1)$33.60Apr 4, 2025154$102.63+95.5%+205.4%
SOBO$23.55 (close, Oct 8)$21.83Apr 8, 2025182$35.96+52.7%+64.7%
AMTM$32.25 (close, Sep 30)#$16.43Apr 8, 2025190$21.87−32.2%+33.1%

Sort: by spinoff date, most recent first. Post-Spin Low = lowest closing price since the first regular-way trading day; days are calendar days from the Day-1 date shown.

  • New lows set in October:
    • ADIG $15.22 (Oct 19, day 76)
    • RNA $7.61 (Oct 19, day 235)
    • FDXF $107.95 (Oct 21, day 142)
    • THRM $26.15 on its Q3 day (Oct 22)
    • All recovered by the pricing date: +14.8%, +8.7%, +16.8% and +18.4% respectively.
  • Octave’s Day-1 base is corrected from the ≈$20.35 open used since June to the $17.05 first-day close (the profile’s finding; the open was most likely a when-issued or Stockholm print). Its return was −7.2% on the old base last edition; it is +27.3% now on the new one.
  • Millrose equalled its post-spin low ($21.22) on October 14, 2026, during the short-report episode; the original date is kept.
  • MSGR’s Day 1 is its first regular-way close (October 27); its when-issued prints (from October 21) are excluded.
  • VYLR’s Day 1 is corrected to $68.26, the post-auction close on 15.0M shares (last edition: ≈$69).
  • # Amentum’s Day-1 close was an index-inclusion print; see the September edition.

Table C: SpinCo Performance Since Last Report (Sep 30 → Oct 30, 2026)

TickerSep 30 CloseOct 30 Close% ChangeCurrent Rating
TRAX$35.44$45.08+27.2%⚠️ NOT RATED
AMTM$18.12$21.87+20.7%⭐⭐⭐ B — ACCUMULATE ⬇️
FDXF$109.38$126.04+15.2%⭐⭐⭐ B+ — TRIM ⬇️
OCTV$18.89$21.71+14.9%⭐⭐⭐ B — TRIM ⬇️
MICC$17.78$19.87+11.8%⭐⭐⭐⭐ A- — HOLD
LION$11.20$12.45+11.2%⭐⭐⭐⭐ BUY (legacy)
MBGL$17.15$18.91+10.3%⭐⭐⭐⭐ A — BUY
SOBO$33.13$35.96+8.5%⭐⭐⭐ B — HOLD
SOLS$56.32$60.55+7.5%⭐⭐⭐ A- — HOLD
RNA$8.28$8.27−0.1%⚠️ NOT RATED
HONA$154.97$154.15−0.5%⭐⭐⭐ B+ — ACCUMULATE ⬇️
VSNT$31.70$31.42−0.9%⭐⭐⭐ B — ACCUMULATE
MRP$25.97$25.62−1.3%⭐⭐⭐ B — HOLD ⬇️
MFP$40.82$40.12−1.7%⭐⭐⭐ B+ — TRIM ⬇️
ADIG$17.92$17.48−2.5%⭐⭐⭐ B — HOLD
RAL$69.17$67.21−2.8%⭐⭐⭐ A- — TRIM ⬇️
JAN$29.63$28.52−3.7%⭐⭐⭐ BUY (legacy)
NVRI$19.53$18.42−5.7%⭐⭐⭐ B — HOLD
MMED$19.47$18.28−6.1%⚠️ NOT RATED
STRZ$23.57$22.09−6.3%⭐⭐⭐ HOLD
Q$125.74$116.67−7.2%⭐⭐⭐ A- — HOLD
VGNT$44.94$41.06−8.6%⭐⭐⭐⭐ B+ — ACCUMULATE ⬇️
ECG$117.52$102.63−12.7%⭐⭐⭐ B+ — HOLD
CHRN$19.73$14.38−27.1%⚠️ NOT RATED
SNDK$1,739.89$1,150.89−33.9%⭐⭐ B — TRIM ⬇️

Sort: by % change since last report, best first.

  • Nine of twenty-five rose; the median name fell 1.3% (MRP), while the S&P 500 fell 0.9% (SPY $762.63 → $755.72). In September, five rose and the median fell 11.0%.
  • The three names added this edition have no September 30 price and are not ranked: MSGR +23.0%, VYLR +6.1% and THRM −8.0% from their October Day-1 closes.
  • What moved them was mostly news, not the tape:
    • TRAX on trial data and a $200M PIPE.
    • FDXF on its first standalone results.
    • LION on a reported Legendary offer.
    • CHRN, ECG and SNDK fell with the data-center and memory trade.
  • AMTM and OCTV rose on no company event; Octave tracked the engineering-software rally that followed Schneider’s $22.6B bid for PTC (October 5).

Table D: Parent Company Performance Post-Spinoff

ParentTickerClose on Spinoff DateCurrent (Oct 30)% ChangeNotes
MSG KnickerbockersMSGK$305.42 (Oct 27)$312.90+2.4%(NEW) Was MSG Sports; MSGS + ½ MSGR = $422.15 vs $405.21 pre-spin (+4.2%)
Corteva (New Corteva)CTVA$12.57 (Oct 1)$11.64−7.4%(NEW) CTVA + VYLR = $84.04 vs $77.65 pre-spin (+8.2%); provider rescale ×6.665
ModineMOD$189.21 (Oct 1)$129.76−31.4%(NEW) Renaming vote (Modexus Solutions) Nov 13; data-center cooling de-rating
ResideoREZI$26.17 (Aug 4)$18.73−28.4%Q3 Nov 10
MiddlebyMIDD$139.26 (Jul 7)$118.95−14.6%+14.8% in October
S&P GlobalSPGI$414.97 (Jul 1)$466.55+12.4%Q3 beat and raise; Capital IQ separation review (Oct 27)
Honeywell TechnologiesHON$227.80 (Jun 29)$218.33−4.2%Q3 adj. EPS $2.27 (+34%); guidance raised
FedExFDX$338.49 (Jun 1)$313.28−7.4%Will “fully monetize” its 19.9% of FDXF within 12 months of Sep 30; new CFO Nov 30
HexagonHXGBF$9.00 (May 28)$10.60+17.8%Thin US OTC quote; Q3 Oct 23
Applied DigitalAPLD$39.88 (May 5)$17.82−55.3%Holds ≈97% of CHRN; −26.9% in October
AnaptysBioANAB$50.95 (Apr 20)$48.28−5.2%GSK litigation post-trial hearing Oct 20
AptivAPTV≈$77.69 (pre-spin)$43.93−43.5%Q3 Nov 3
HealthpeakDOC≈$20 IPO ref$19.03−4.8%Q3 Nov 2
MedtronicMDT≈$93.46 (Mar 6)$96.54+3.3%No longer holds any MMED (exchange closed Oct 15)
BDBDX$163.04 (Feb 9)$197.88+21.4%Analyst day Dec 10 (corrected)
ComcastCMCSA$27.80 (Jan 5)$23.22−16.5%Buybacks suspended until the NBCU separation
UnileverUL$61.80 (Dec 8)$65.26+5.6%*Q3 USG 5.2%; Foods/McCormick “on track”
DuPontDD$34.38 (Nov 3)$46.68 (adj.)+35.8%‡1-for-3 reverse split Jun 24
Honeywell (pre-breakup)HON$197.94 (Oct 30)n/mn/m†Superseded by the Jun 29 baseline
FortiveFTV$52.13 (Jun 30 2025)$65.23+25.1%+19.0% in October; FY EPS guide raised
Western DigitalWDC$49.02 (Feb 24 2025)$366.11+646.9%FQ1 revenue +55%; dividend +17%
LennarLEN$119.80 (Feb 7 2025)$86.94−27.4%Counterparty to Millrose’s rental-home purchases
MDU ResourcesMDU$15.10 (Nov 1 2024)$19.72+30.6%
TC EnergyTRP$44.03 (Oct 2 2024)$64.50+46.5%Q3 Nov 5
JacobsJ$129.60 (Sep 30 2024)$154.62+19.3%§+14.3% in October

Sort: by spinoff date, most recent first. * UL share-consolidation adjusted. † Pre-breakup Honeywell line retained for continuity only. ‡ DD split-adjusted; raw $140.05. § Jacobs on the provider-adjusted series. MSGK and CTVA baselines are first regular-way closes after their distributions; the “holder” figures combine one parent share with the SpinCo shares received (1 VYLR per CTVA; ½ MSGR per MSGS) against the last pre-spin close.

Post-Spin Low Recovery — Pattern Analysis (updated)

  • October reversed September for the oldest problem names, on results rather than time.
    • FDXF made a sixth monthly low (October 21, day 142), then rose 14.9% in one session on its first standalone results.
    • ADIG and RNA made lows on October 19 and recovered 15% and 9% without results. ADIG’s next print is November 12; RNA dosed its first trial patient and raised $50M.
    • September’s finding stands: lows set past day 90 are re-pricings, not forced-selling troughs. October adds that they end on information, not on a calendar.
  • Two October spins tested the forced-selling pattern from opposite ends.
    • Vylor had no when-issued market and never traded meaningfully below its first close: the low was $67.26 on day one, 1.5% under.
    • New Corteva (CTVA) traded 88.4M shares on day one, about 20x normal, and fell 7.4% over the month. The selling landed on the parent, which the Vylor profile calls the first parent-side flush in the site’s data.
    • MSG Rangers rose 23% in four sessions on low volume from its first regular-way close.
  • The retained-stake natural experiment resolved.
    • MiniMed’s 90% overhang was removed in a single oversubscribed exchange (proration 18.29%). MMED fell 6.1% in October and set an intramonth low of $16.81 on October 14, the day before settlement, then recovered 8.7%.
    • Removing a static seller produced a one-time supply wave, not a re-rating. That was this report’s stated alternative hypothesis.
    • FedEx’s 10-Q now says its 19.9% of FDXF will be sold within twelve months, which moves the next test of the same question forward to 2027.
  • The data-center trade cut both ways inside one month.
    • CHRN (−27.1%), ECG (−12.7%) and SNDK (−33.9%) fell with the group despite good company news: CHRN’s run-rate contracts, SNDK’s record quarter.
    • Among parents and upcoming names, Modine (−30.7%), Flex (−21.4%) and Eaton (−13.9%) fell together.

Per-name sections below are ordered by spinoff date, most recent first — the same rule as Tables A, B and D. Where a standing company profile exists, its grade and dimension scores are carried; the rating and target are the report’s, set from the profile’s target on the October 30 close and the five-band scale. Lag window = profile price date → October 30.

1. MSG RANGERS (MSGR) ⭐⭐⭐ B — NOT RATED (NEW — completed Oct 26)

  • Current Price: $218.49; +23.0% vs the $177.61 first regular-way close (October 27).
  • Completion (8-Ks October 26):
    • 9,794,568 Class A and 2,264,754 Class B shares distributed at 1 per 2 MSGS.
    • NHL Transfer Consent Agreement (October 23): any future transfer or relocation needs NHL consent.
    • §355 opinion from Sullivan & Cromwell.
    • Dolan registration rights and standstill in effect.
    • James Dolan received a one-time $10M cash “distribution award” and is Executive Chairman and CEO of both companies.
    • About $20M of tax from accelerating Rangers deferred revenue stays with MSGK, with no reimbursement.
  • Grade B (2.60) maintained; the report owns it. The site’s pre-spin analysis is substantial but has no scorecard, so it is not a Deep profile.
    • ⚠️ Correction: FY2026 pro-forma adjusted operating loss was $(21.5)M, operating loss $(31.1)M, on $341.5M of revenue (Form 10/A, September 30). Last edition printed $(16.3)M.
    • Financial Profile stays at 2. The $10M award is a governance negative inside a Management score already at 2.
  • NOT RATED. The pre-spin analysis gives fair values but no weighted cases: MSGR $250, MSGK $360 (mid franchise value less a 25% discount, priced October 5). At $218.49 MSGR is 13% below the MSGR figure; MSGK at $312.90 is 13% below its own. Holders of record got $422.15 of value for a $405.21 share (+4.2%).
  • Parent MSGK $312.90 (+2.4% from its first regular-way close).
  • SEC — MSG Rangers 8-K: completion of the distribution (October 26, 2026) · SEC — MSG Knickerbockers 8-K (October 26, 2026) · SEC — MSGR 8-K: Form 10 effective (October 9, 2026)

2. VYLOR (VYLR) ⭐⭐⭐ A- — SELL (NEW — completed Oct 1; profile’s provisional HOLD → SELL)

  • Current Price: $72.40; +6.1% vs the $68.26 first close (corrected from ≈$69). Low $67.26 on October 2.
  • The profile (day one, October 1, priced at $68.26) re-scores the grade A- 3.80 → A- 3.73, within band:
    • Competitive Position 4 → 4.5, on a seven-year Seed record: positive price every year since 2020, margin 13.7% → 26.6%.
    • Strategic Rationale 4 → 3: ≈$3.8B of cash sent to EIDP and funded by Vylor-side borrowing; Vylor’s 62% of unassigned liabilities; and the states’ fraudulent-transfer claim, which the injunction rulings did not dispose of.
    • Financial 4.0, Management 4.0 and Acquisition 2.0 are unchanged.
    • This overturns last edition’s statement that the California action “un-anchors no dimension”.
    • Grade change: A- (3.80) → A- (3.73), a data re-derivation, not a business change.
  • The market’s verdict on day one: one old share became one of each, worth $80.83 (+4.1%), split 84% Vylor / 16% New Corteva. The pre-spin analysis expected about a third for Corteva. At the close Vylor traded at ≈17.3x 2026E EBITDA, near the top of seed-industry takeover multiples.
  • ⚠️ Lag window (Oct 1 → Oct 30) contains a thesis-relevant event.
    • October 1: 15 states and one sovereign sued in the Southern District of Indiana.
    • October 9: a TRO barred dividends, buybacks and out-of-ordinary-course asset disposals at both companies.
    • October 10: the court stayed the order pending a Seventh Circuit motion, relying on Vylor’s representation that it will not declare dividends or buy back shares while the motion is pending. The motion and appeal were still pending at the pricing date.
  • The report’s three steps:
    1. Re-rate: provisional HOLD → SELL, target $54. At $72.40 the expected return is −25.4%, the SELL band, and the profile’s own instruction is met: “If Vylor still trades above $65 once the first-week analysis is in, the follow-up should move it to SELL. Do not buy above $58.” The first-week follow-up was never published, and the lag window adds the TRO. The report owns the rating on a lag-window event, per the division of authority; the profile’s page still shows HOLD until its follow-up. This is a call on price against an excellent business, not a view that the business has weakened — the grade stays A-.
    2. Hold the grade. A- (3.73).
    3. Scope the re-grade. The TRO un-anchors Management & Governance (capital allocation: the $3B buyback and ≈15%-of-OCF dividend are both suspended in practice) and re-tests Strategic Rationale, whose litigation charge was set before the order existed. Competitive and Financial are not touched.
  • Parent New Corteva (CTVA) $11.64, −7.4% from its $12.57 first close.
  • SEC — Vylor 8-K: temporary restraining order and stay (October 2026) · SEC — Corteva 8-K: TRO · SEC — Vylor 8-K: distribution completed (October 1, 2026)

3. GENTHERM (THRM) — MODINE PERFORMANCE TECHNOLOGIES RMT ⭐⭐⭐ B+ — HOLD (NEW — closed Oct 1; no valuation)

  • Current Price: THRM $30.95, −8.0% from its October 1 close of $33.63; low $26.15 on October 22, the day of its Q3.
  • Final terms (8-Ks October 1):
    • 0.44619 THRM per MOD share; 23,735,961 shares issued; former Modine holders 43.62%, Gentherm holders 56.38%.
    • SpinCo borrowed a $250M senior secured term loan (BofA), guaranteed by Gentherm. This is the first disclosure of the SpinCo’s debt.
    • $155,991,275 was paid to Modine, which used it to prepay its revolver.
    • Gentherm holders received a $2.07 special dividend ($63.5M) on October 7.
    • ⚠️ Correction: last edition, from the September 17 revised terms, gave $159M and $1.90 (≈$58.35M). The closing figures differ.
    • Gentherm keeps its name and ticker; the business is a Gentherm division; Paul Mascarenas joined the board.
  • Q3 (October 22; legacy Gentherm only):
    • Revenue $405.1M (+4.7%); adjusted EBITDA $45.0M, 11.1% (vs 12.7%); adjusted EPS $0.33 (vs $0.73).
    • 2026 guidance now includes Q4 of the acquired business: revenue $1.825–1.925B, adjusted EBITDA $210–230M. That implies ≈$275M of revenue and $25–30M of EBITDA from Performance Technologies in Q4, a ≈10% margin.
    • $60M of stock bought back in October; ≈$340M remains on the $400M authorisation.
  • B+ (3.20) carried; HOLD, no valuation. The implied ≈10% margin on the acquired business confirms the Financial Profile score of 3, which rested on undisclosed margins.
  • Parent Modine (MOD) $129.76, −31.4% from October 1 with no company news. The data-center cooling group sold off (Part 2 §3), and last edition’s “prefer Modine” call is the month’s worst result. Renaming vote (Modexus Solutions) November 13; FQ2 November 4.
  • SEC — Gentherm 8-K: completion of the combination (October 1, 2026) · SEC — Modine 8-K (October 1, 2026) · SEC — Gentherm Q3 2026 results (October 22, 2026)

4. ADI GLOBAL DISTRIBUTION (ADIG) ⭐⭐⭐ B — HOLD (target $18 → $16)

  • Current Price: $17.48 (−2.5%); −20.5% vs Day 1. New post-spin low $15.22 on October 19 (day 76), +14.8% off it.
  • The profile’s full update (October 23, priced at $16.48) holds B (2.73) and cuts the target to $16 (cases $27.24 / $18.02 / $9.13, weights 10/55/35).
    • The October fall (−11.1% from September 28 to October 22, while distributors rose 5.2%) was company-specific: Evercore initiated at In Line ($23), and J.P. Morgan cut its target to $20.
    • Resideo’s former CEO Jay Geldmacher sold 353,287 shares (≈$7.5M) between August 14 and October 12. No ADI officer or director has traded on the open market.
    • Short interest has risen at every report, to 4.8%.
    • Covenants pass even in a 2027 recession: leverage peaks at ≈3.3x against a 4.25x limit.
  • Lag window (Oct 22 → Oct 30): +6.1% on no event. Rating: HOLD, target $16. At $17.48 the price is 9% above target, inside the HOLD band (up to 11% above). Thesis-breaking: 2026 adjusted EBITDA below $240M. Q3 November 12.

5. MIDERA FOOD PROCESSING (MFP) ⭐⭐⭐ B+ — TRIM ⬇️ (HOLD → TRIM; first score B+ 3.23; target $35)

  • Current Price: $40.12 (−1.7%); +9.6% vs Day 1. It has never closed below its debut.
  • The profile’s first full analysis (October 28, priced at $42.34) gives the first weighted score: 3.23: Financial 3.0, Competitive 3.5, Strategic 3.5, Management 3.0, Acquisition 3.0. B+ is unchanged.
    • The record is worse than the reports implied. The adjusted EBITDA margin was 23.1% / 24.1% / 17.8% in 2023–25 and 16.3% in 1H26. Sales ex-acquisitions fell 4.4% in 2025.
    • The separation terms are better: Midera paid Middleby $233.0M, and net debt is $208.1M (≈1.3x).
    • ⚠️ Correction: last edition estimated net debt at ≈$0.3B. EV at the September 30 close was ≈$2.05B, ≈12.2x guided EBITDA, not 12.8x.
    • The 2026 guide needs a 19.3% second-half margin; the Q2 margin was 17.0%. Backlog is a record $446M (+51%).
    • Garden Investment Management holds 7.5% (13D). The first standalone acquisition, Phoenix Innovations, was announced October 23.
  • Rating: HOLD → TRIM, target $35 (cases $48.44 / $36.20 / $22.00, weights 20/55/25). At $40.12 the price is 15% above target; expected return −12.8%, the TRIM band. The profile kept HOLD ahead of Q3 (≈November 12) and noted an 8.2% discount rate would justify the price; the report applies the band — the second-half margin the price needs (19.3%) has not yet been shown. HOLD returns below ≈$38.85. Thesis-breaking: 2026 standalone EBITDA below $150M.

6. MOBILITY GLOBAL (MBGL) ⭐⭐⭐⭐ A — BUY (target $28 → $27)

  • Current Price: $18.91 (+10.3%); −10.8% vs Day 1, +10.3% off the September 30 low.
  • The profile’s October updates (Oct 5, 9 and 14; priced at $18.11) keep A (4.35) but carry two data corrections that cut the target $28 → $25, then a re-weighting to $27:
    • The August analysis missed that the CARFAX bundled dealer package had failed and been reversed from June, and that the August 7 guidance was a cut.
    • It did not deduct stock compensation, now ≈3% of revenue.
    • The October 9 update also finds September’s fall was an auto-sector sell-off, not the information-services de-rating last edition described (correction).
    • MBGL sits in the S&P SmallCap 600, classified as an industrial.
  • Rating: BUY, target $27 (cases $40.59 / $30.94 / $12.92, weights 15/55/30). At $18.91: expected return +43%, gain-to-loss ≈6:1. Lag window (Oct 13 → Oct 30): +4.4% on no event.
  • ⚠️ Not yet scored: the profile flags that the October evidence on CARFAX pricing pressure (≈4 of the 7.4 points of H1 growth was price) has not been scored into Competitive Position (5.0). That is the dimension Q3 (November 12) re-tests.
  • Parent SPGI $466.55 (+12.4%): Q3 beat and raise, and a strategic review of Capital IQ (October 27) that could make S&P Global a two-time spinner.

7. HONEYWELL AEROSPACE (HONA) ⭐⭐⭐ B+ — ACCUMULATE ⬇️ (BUY → ACCUMULATE; target $195 → $192)

  • Current Price: $154.15 (−0.5%); −30.0% vs Day 1. It stayed above the $151.58 September low.
  • Q3 (October 28):
    • Sales $4,644M (+2% organic); segment margin 25.0%, ≈23.9% excluding ≈$50M of tariff refunds.
    • Adjusted EPS $2.21 (vs ≈$2.00 consensus); FY adjusted EPS guidance raised to $7.85–8.00.
    • Backlog $19.3B (+12%); aftermarket only +2%, supply-constrained.
    • First dividend: $0.40 a quarter (record November 13). No buybacks under the $3.5B authorization. A $500M Tempe plant is planned.
    • The stock fell 9.6% on October 29: the CFO guided to no Q4 refunds and an exit margin in the “mid-23s”, implying a flat 2027.
  • The profile’s Q3 update (rated at the $160.04 October 29 close): B+ (3.20) held; BUY → ACCUMULATE, target $192 (cases $237.57 / $201.11 / $107.00, weights 15/70/15). The profile’s October 13 corrections: there is no term loan, and the revolvers total $4.0B, not $1.25B.
  • Rating: ACCUMULATE, target $192. At $154.15 the expected return is +24.6%, a hair under the BUY line; the profile’s own Buy level is “below about $154”. This is a re-rating onto the new scale plus a modest target cut, not a thesis change. The profile did not re-score Management for the securities class action (lead-plaintiff deadline November 23); that remains open.
  • Parent HON $218.33 (−4.2%).

8. FEDEX FREIGHT (FDXF) ⭐⭐⭐ B+ — TRIM ⬇️ (HOLD → TRIM; target $108 → $112)

  • Current Price: $126.04 (+15.2%); −15.7% vs Day 1. Sixth consecutive monthly low, $107.95 on October 21 (day 142), then +14.9% on October 30 on results.
  • First standalone results (October 29; the four months June–September):
    • Revenue $3,281M (+9.2%) on shipments −1.4%. Revenue per hundredweight was +8.6%, but only 0.3% of it was base price (Old Dominion 5.1%, XPO 3.6%).
    • Adjusted operating income $510M (+16.4%); adjusted operating ratio 84.5%.
    • Q4 guidance implies an OR of ≈91.6%; the 2027 framework is +4–6% revenue.
    • A 6.9% general rate increase lands January 8.
  • FedEx’s 10-Q (October 28): it expects to “fully monetize” its 19.9% (29,751,545 shares) within 12 months of September 30, well ahead of the June 2028 tax deadline. FedEx marked a $1.2B loss on the stake.
  • The profile’s full update (October 30, priced at the same $126.04): B+ (3.15) held; HOLD → TRIM, target $112 (cases $143.67 / $115.88 / $78.48, weights 20/55/25; expected return −11%, gain-to-loss 0.20). Correction: the retained stake is 29,751,545 shares, not ≈30.1M.
  • Rating: TRIM, target $112. The rally prices the best case: the price-implied weights are 41/55/4. ≈21–24M shares of net supply arrive within a year. HOLD returns below ≈$124.55.

9. NEW ENVIRI (NVRI) ⭐⭐⭐ B — HOLD (legacy)

  • Current Price: $18.42 (−5.7%); −4.1% vs the June 2 regular-way close, plus the $15.00/share cash. No October development; Q3 expected mid-November. B — HOLD.

10. OCTAVE INTELLIGENCE (OCTV) ⭐⭐⭐ B — TRIM ⬇️ (HOLD → TRIM; target $19.50 → $19, proposed)

  • Current Price: $21.71 (+14.9%); +27.3% vs the corrected $17.05 Day-1 close.
  • The profile’s full update (October 26, priced at $21.29):
    • The rise tracked the engineering-software group (+22.6%), lifted by Schneider’s $22.6B cash bid for PTC (October 5).
    • Base case unchanged; target $19 (proposed).
    • Insiders have bought 255,140 shares (≈$4.73M) and sold none.
    • Two material weaknesses in internal control were omitted on September 8 (correction).
    • The September claim of a §355(e) bar on a sale to May 2028 is withdrawn: the tax disaffiliation agreement has no restricted period. That makes a takeover easier than last edition implied.
  • Grade B (6.30/10 on the profile’s instrument). ⚠️ A methodology 1–5 re-score is still open; the October update did not do it.
  • Rating: HOLD → TRIM, target $19 (proposed). At $21.71 the price is 14% above target; expected return −12.5%, the TRIM band. The profile kept HOLD on insider buying and a half-point discount-rate gap; the report applies the band — the price rose on a sector re-rating (the PTC bid), not on Octave’s numbers. Q3 on November 12 tests ARR (thesis-breaking: ARR declining year on year); HOLD returns below ≈$21.09.
  • Parent Hexagon $10.60 (+17.8%).

11. CHRONOSCALE (CHRN) ⚠️ — NOT RATED

  • Current Price: $14.38 (−27.1%); +8.8% vs Day 1, at its October low on the pricing date.
  • October:
    • New and expanded contracts support $1B of annualised run-rate revenue by calendar Q3 2027; $328.2M of customer prepayments received.
    • A $500M shelf (S-3, October 6) that also allows selling stockholders.
    • The FQ1 10-Q says the going-concern doubt is “alleviated”; FQ1 revenue $41.5M (+148%).
    • The B. Riley term loan still matures November 12, with no extension disclosed.
  • Annual meeting November 6. Parent APLD $17.82 (−55.3%). NOT RATED (speculative).

12. FIRST TRACKS BIOTHERAPEUTICS (TRAX) ⚠️ — NOT RATED

  • Current Price: $45.08 (+27.2%); +142.4% vs Day 1.
  • Positive Phase 1b celiac gluten-challenge data for ANB033 (October 12): placebo-adjusted Vh:Cd +0.49 (p = 0.009) and no safety signals; the stock rose ≈20% that day.
  • $200M PIPE at $32.75 (closed October 19), with resale registration effective October 29.
  • NOT RATED (speculative); the PIPE price is 27% below the current quote.

13. VERSIGENT (VGNT) ⭐⭐⭐⭐ B+ — ACCUMULATE ⬇️ (BUY → ACCUMULATE; target $62 → $48)

  • Current Price: $41.06 (−8.6%); +47.4% vs Day 1, at its October low on the pricing date.
  • The profile cut the target twice in October, to $54 (October 8) and $48 (October 15, priced at $42.56), holding B+ (3.20):
    • About half of reported growth is copper and currency pass-through (adjusted growth 5% in Q2, against 10.8% reported).
    • 2026 EBITDA guidance ($950–1,030M) sat below what the August valuation used (correction).
    • Three carmakers are 52% of sales.
    • A $250M buyback authorised in April is unused.
  • Rating: ACCUMULATE, target $48 (cases $81.15 / $55.69 / $22.60, weights 10/60/30). Expected return +17%. Q3 November 4. Parent APTV $43.93.

14. JANUS LIVING (JAN) ⭐⭐⭐ — BUY (legacy)

  • Current Price: $28.52 (−3.7%); +20.8% vs Day 1 / +42.6% vs the IPO. No October development; parent Healthpeak reports November 2. BUY (legacy, no target).

15. MINIMED (MMED) ⚠️ — NOT RATED

  • Current Price: $18.28 (−6.1%); −4.0% vs the open and −8.6% vs the IPO.
  • Medtronic is gone from the register. The exchange offer closed October 15: oversubscribed (297.5M MDT tendered; proration 18.29%), at the 4.5939 cap. All 252,813,348 MMED shares exchanged; Medtronic owns none. The four Medtronic designees left the board (11 → 8) and Amy Bricker joined.
  • The stock fell to $16.81 on October 14 as the exchanged supply arrived, then recovered 8.7%.
  • NOT RATED until a profile values it as a fully independent company. Q2 FY27 is the first quarter with no controlling holder.

16. ATRIUM THERAPEUTICS (RNA) ⚠️ — NOT RATED

  • Current Price: $8.27 (flat); −43.9% vs Day 1; new low $7.61 on October 19 (day 235).
  • $50M PIPE at $7.93 (October 7–8); runway extended through 2028. First patient dosed in the Corventis Phase 1/2 trial (October 27), ahead of the year-end guidance. NOT RATED (speculative).

17. WATERS (WAT) — BD BIOSCIENCES RMT ⭐⭐ HOLD (legacy)

  • WAT $462.72 (+5.3%); no October filing. Parent BDX $197.88 (+21.4%); ⚠️ BD’s analyst day is December 10, not November as last edition said (correction). HOLD.

18. VERSANT (VSNT) ⭐⭐⭐ B — ACCUMULATE (target $42 → $36)

  • Current Price: $31.42 (−0.9%); −30.4% vs Day 1.
  • The profile moved three times in October: ACCUMULATE $42 (Oct 5) → HOLD $41 (Oct 7) → HOLD $36 (Oct 13, priced at $30.60), holding B (2.75). The October 7 move corrected the case’s central comparison: the market’s implied FCF decline had been compared with a revenue decline.
  • ⚠️ Corrections that touch last edition’s text:
    • Debt principal is $3.0B, not $3.2B; net debt was ≈$1.52B at June 30.
    • The underlying revenue decline is −4.1%, not −2.5%, after the SportsEngine sale and a one-off licensing deal.
  • Rating: ACCUMULATE, target $36 (cases $78.65 / $32.98 / $17.96, weights 15/60/25). At $31.42 the expected return is +14.6%, the ACCUMULATE band. The profile’s HOLD was set before the scale existed, and its tracker already lists HOLD → ACCUMULATE for the next update. This is the report applying the scale, with the profile’s target.
  • Q3 November 3. Parent CMCSA $23.22.

19. MAGNUM ICE CREAM (MICC) ⭐⭐⭐⭐ A- — HOLD (first grade A- 3.68)

  • Current Price: $19.87 NYSE (+11.8%) / €17.70 Amsterdam; +33.4% vs Day 1.
  • First grade from the profile (October 9): A- (3.68): Financial 3.5, Competitive 4.0, Strategic 3.5, Management 4.0, Acquisition 3.0. Published here for the first time.
  • Q3 trading update (October 29):
    • Revenue €2.51B (+12.1%); organic +9.6% (volume +7.3%, price +2.2%), 2–3 points of it from an extended European summer.
    • FY organic growth raised to ≈5.5%; margin guidance unchanged.
    • Unilever’s 19.9% is still unsold.
  • Rating: HOLD, target €16.5 ($18.4) (profile, October 30; cases €23.88 / €17.95 / €8.55, weights 15/60/25). At €17.70 the expected return is ≈−7%; the profile’s TRIM line is ≈€18.3 ($20.5). Thesis-breaking: two consecutive half-years of falling volume.

20. QNITY ELECTRONICS (Q) ⭐⭐⭐ A- — HOLD (target $132 → $123)

  • Current Price: $116.67 (−7.2%); +11.1% vs Day 1.
  • The profile’s October updates (Oct 9 and 15, priced at $121.62) hold A- (3.58) and cut the target to $118, then re-weight it to $123.
    • ⚠️ Correction: last edition said the North Carolina settlement “leaves Qnity’s $43M indemnification liability unchanged.” The $43M is only the North Carolina share. Qnity has $253M recorded for its 44% of DuPont’s legacy liabilities, with up to ≈$100M more reasonably possible.
    • California asked the PFAS court on August 6 to add Qnity as a defendant on a fraudulent-transfer theory, the same theory now being litigated against Vylor. There is no ruling yet.
    • CFO Ken Rizvi started October 1.
  • Rating: HOLD, target $123. Expected return +5.4%. Q3 November 4; China’s export-control suspension expires November 10.

21. SOLSTICE ADVANCED MATERIALS (SOLS) ⭐⭐⭐ A- — HOLD (target $62 → $57)

  • Current Price: $60.55 (+7.5%); +21.0% vs Day 1.
  • The profile’s update (October 15, priced at $60.13) holds A- (3.63) and cuts the target to $57 on a data correction: the August valuation did not deduct General Atomics’ 50% of ConverDyn (≈−$4.50 a share). Solstice is in the S&P MidCap 400, not the S&P 500 (correction to Table A). The Metropolis lawsuits settled in principle for ≈$80M.
  • ⚠️ Still open from September: the Competitive Position rationale (4.5) still counts three franchises “post-Element”. The termination un-anchored that dimension, and it has not been re-derived.
  • Rating: HOLD, target $57. Expected return −5.9%. Q3 November 4.

22. RALLIANT (RAL) ⭐⭐⭐ A- — TRIM ⬇️ (HOLD → TRIM)

  • Current Price: $67.21 (−2.8%); +38.6% vs Day 1. No October filings or news.
  • A- (3.50); target $58 (the August profile; a full update is planned after Q3). The price is 16% above target; expected return −13.7%, the TRIM band. Last edition said the rating “would move to trim if the move holds into the Q3 print”; it has held for two months. Rating: HOLD → TRIM, target $58 (report, on price). Q3 is November 4 and the profile’s full update follows on November 5–6; a raised target there would move it back.
  • Parent FTV $65.23 (+25.1%): Q3 beat; guidance raised.

23. STARZ (STRZ) & LIONSGATE STUDIOS (LION) — PARENT SPLIT

  • STRZ: $22.09 (−6.3%); +97.2% from reference.
    • The Verizon Fios blackout ended after about two weeks; terms were not disclosed.
    • Q3 (October 29): revenue $322.4M; adjusted OIBDA $44.2M (≈13.7%), more than double a year ago; leverage 2.8x; every 2026–27 target reaffirmed.
    • HOLD (legacy).
  • LION: $12.45 (+11.2%); +52.8% from reference.
    • Bloomberg reported on October 20 that Legendary (Apollo-backed) made a formal takeover offer (secondary; no company confirmation), and LION rose ≈15% that day.
    • JPMorgan’s September Underweight put the odds of a sale at 20%. BUY (legacy): the takeover thesis now has a named bidder.

24. SANDISK (SNDK) ⭐⭐ B — TRIM ⬇️ (HOLD → TRIM; target ≈$914)

  • Current Price: $1,150.89 (−33.9%); +2,268.1% vs Day 1. −13.5% on October 30 alone, on 17.4M shares.
  • The profile’s full update (October 23, priced at $1,260.93): B (2.93) held; HOLD (no target) → SELL, target $860 (proposed on the page; cases $1,399 / $774 / $407, weights 25/55/20).
    • The price was implying 78% weight on management’s plan, about four more years of current memory prices.
    • Eight long-term contracts commit ≥$93.9B, with price floors.
    • Capacity: the >$31B Japan fab plan lands from ≈FY2029.
  • FQ1 FY27 (October 29) beat everything:
    • Revenue $11.03B; non-GAAP gross margin 85.1%; EPS $49.51; Q2 guide $12.2–12.6B.
    • $5.0B of buybacks at ≈$1,560 a share.
    • The owner kept SELL; a re-strike to ≈$914 waits for the 10-Q.
  • Rating: HOLD → TRIM, target ≈$914. The profile’s $860 (proposed, priced October 22) predates the FQ1 results; re-anchored on them, the cases rise to ≈$1,485 / $827 / $440 and the target to ≈$914 — an estimate the profile will publish with the 10-Q. At $1,150.89 that is an expected return of −20.6%, the TRIM band (on $860 it would be −25.3%, SELL). The report uses the post-results figure because its pricing date is after the results.
  • 8-for-1 split: record November 9, split-adjusted trading from November 20. Divide every figure here by 8 from then (≈$914 → ≈$114).

25. MILLROSE PROPERTIES (MRP) ⭐⭐⭐ B — HOLD ⬇️ (BUY → HOLD, on watch; first grade B 2.70)

  • Current Price: $25.62 (−1.3%); +9.1% vs Day 1. Equalled its post-spin low ($21.22) on October 14, then recovered 20.7%, +7.2% on Q3.
  • The profile’s first full analysis (October 11) and Q3 update (October 30, priced at $25.62): first grade B (2.70): Financial 3.0, Competitive 3.0, Strategic 3.0, Management 2.0, Acquisition 2.0.
  • What happened:
    • Amendments dated August 27 (filed September 1) let Millrose buy completed Lennar homes for rent. Hunterbrook’s short reports (October 2 and 8) were followed by a Citizens/JMP downgrade and a class action (S.D. Fla., October 9; lead-plaintiff deadline December 8).
    • Q3 (October 27) sized it: 1,233 homes, ≈$333M ($120M of equity, $213M of limited-recourse debt), plus ≈$150M of build-to-rent contracts, ≈$480M gross in all.
    • Not disclosed: independent-director approval and a cap.
    • Also in Q3: AFFO $0.80; outlook raised to $0.82–0.84 a quarter; first buyback, $250M. The Dream Finders–Beazer financing closed October 20.
  • ⚠️ Corrections:
    • Last edition said “the land-bank model has not changed”. The rental amendments pre-dated it, so that was an omission.
    • The March 2 report said Lennar retained ≈20%. Lennar exchanged that stake in November 2025 and holds almost none.
  • Rating: HOLD, ON WATCH, target $25 (cases $35.86 / $26.44 / $16.61, weights 15/60/25). No new position while on watch, whatever the price. The watch runs to the 10-Q (by November 9). SELL if it shows above-market purchases.
  • Parent LEN $86.94 (−27.4%).

26. EVERUS CONSTRUCTION (ECG) ⭐⭐⭐ B+ — HOLD

  • Current Price: $102.63 (−12.7%); +95.5% vs Day 1.
  • No October development. No buyback was announced before the tax-matters restrictions lapse on November 1. Q3 is expected early November.
  • B+ (3.18) — HOLD, target $97 (profile, September). The price is 6% above target, inside HOLD; the profile’s line is “do not add above $97; accumulate below $80”. The October fall came with the data-center contractors, not company news.

27. SOUTH BOW (SOBO) ⭐⭐⭐ B — HOLD

  • Current Price: $35.96 (+8.5%); +52.7% vs the first NYSE close. No October development.
  • Q3 November 4 after the close, with a 2027 outlook; it is the first period on the new uncommitted tolls.
  • B (2.90) — HOLD, target US$33. The price is 9% above target, at the top of HOLD.

28. AMENTUM (AMTM) ⭐⭐⭐ B — ACCUMULATE ⬇️ (BUY → ACCUMULATE; target $25)

  • Current Price: $21.87 (+20.7%); −32.2% vs the Day-1 auction print.
  • Lag window (Sep 22 → Oct 30):
    • The only filing is an October 2 8-K extending Executive Chair Steven Demetriou’s agreement with severance removed.
    • No buyback was announced after the tax-matters restriction lapsed on September 28.
    • The shares rose 11% from the profile’s $19.70 price on no company event.
  • Rating: BUY → ACCUMULATE, target $25 (unchanged). At $21.87 the expected return is +14.3%, the ACCUMULATE band. BUY on the new scale needs +25% and a 3:1 gain-to-loss, and the profile has no scenario cases to compute one. This is a price-driven re-rating owned by the report, not a re-underwriting.
  • ⚠️ Correction (from the profile, October 20): last edition repeated the profile’s claim that RMTs are “the universe’s worst structure — 12 of 13 lagged the index”. A test of 308 separations does not support that ranking.
    • RMTs’ median annual excess return was −10.4 points against −8.7 for classic spinoffs (p = 0.67). Split-offs (−15.2) and unclassified rows (−20.7) sat lower.
    • Amentum’s own record is unchanged (−38.3 points a year), as are Strategic Rationale 2.0 and the B (2.73). Those rest on deal-specific facts: $911M to Jacobs from same-day debt, and the parent stake sold at a 17.5% discount.
    • This corrects the analysis, with no change in the business.
  • Sell the thesis if RPO falls again in the late-November 10-K. Parent Jacobs $154.62 (+19.3%).

Part 4: OUTLOOK & UPCOMING CATALYST CALENDAR

November 2026:

  • October 31 (post-pricing): UPM → WISA demerger effective; first trade November 2 (non-US)
  • November 1: Everus tax-matters restrictions on a sale and on buybacks lapse
  • ⚠️ November 2: Flex EGM on the Axiom capital reduction and bonus issue (three-quarters vote)
  • November 3: Russ Torres starts at KDP; DS Smith plc Capital Markets Day (International Paper; sale talks live); Versant Q3; Aptiv Q3
  • November 4: Ralliant, Qnity, Solstice, Versigent and South Bow Q3 (South Bow gives its 2027 outlook); Modine FQ2
  • November 5: TC Energy Q3; Solventum Q3
  • November 6: ChronoScale annual meeting
  • By November 9: Millrose 10-Q — the watch decision (independent approval, pricing and a cap on rental purchases); Sandisk 10-Q (target re-strike) and split record date
  • November 10: Axiom Innovation Day; Resideo Q3; China’s export-control suspension expires (Qnity)
  • November 11: CMA Phase 1 deadline, Unilever Foods/McCormick; KBR investor day
  • November 12: Trinzic investor day; ADI Global, Mobility Global and Octave Q3; ChronoScale’s B. Riley loan matures
  • ≈November 12: Midera Q3
  • November 13: Modine’s Modexus renaming vote; HONA dividend record date; Russell preliminary lists
  • November 20: Sandisk trades split-adjusted (8-for-1)
  • November 23: HONA class-action lead-plaintiff deadline
  • Late November: Amentum FY2026 10-K — remaining performance obligations decide the ACCUMULATE
  • Pending, no date: Seventh Circuit ruling on the Vylor/Corteva TRO stay — the dividend and buyback freeze

December 2026:

  • December 7: Dana special meeting on the Mobility combination
  • December 8: J&J Enterprise Business Review (DePuy pro formas expected); Millrose class-action lead-plaintiff deadline
  • December 8–9: GPC and Motion investor days
  • December 10: BD analyst day
  • December 11: Russell reconstitution effective (MBGL, MFP, OCTV index moves)
  • By year-end: Adaptive Biotechnologies separation path; Barrick F-1 (or the report downgrades Strategic Rationale)

2027:

  • January 4: KBR → Trinzic distribution
  • Q1: Eaton Mobility + Dana RMT (exchange offer, close ≈end of Q1); Flex → Axiom; Genuine Parts → Motion; Keurig Dr Pepper Global Coffee; International Paper DS Smith (or sale); North American Barrick IPO (moved)
  • Mid: Comcast/NBCUniversal; Unilever/McCormick close; J&J DePuy Synthes (now mid-2027); L3Harris Missile Solutions IPO (preferred assumes before Dec 31, 2027)
  • Q2–Q3: Textron Industrial (sale or spin)
  • H2: National Fuel Gas → IUG; McKesson Medical-Surgical; HF Sinclair Lubricants & Specialties; Solventum HIS (likely sale); ABF → Primark (December, non-US)
  • By year-end: Abbott → Nutrition; Flex/Axiom preferred redemption trigger if the spin has not occurred (December 31)

Watch items / status changes this cycle:

  • ⬆️ KDP → Global Coffee B (2.95) → B+ (3.15): CEO named
  • ⬇️ International Paper → DS Smith B → B-: EMEA loss and impairment; sale talks confirmed
  • 🆕 Abbott → Nutrition B (2.90) and National Fuel Gas → IUG B (2.75), both provisional; Eaton → Mobility/Dana first score B (2.90) on the S-4
  • ✅ Completed: MSG Rangers (Oct 26), MiniMed full exit (Oct 15), Vylor and Gentherm (Oct 1), Toro → AI OKTO (Oct 8)
  • Vylor A- 3.80 → 3.73 (profile); rated SELL ($54) on price, the profile’s own $65 trigger and the TRO on dividends and buybacks
  • 🆕 First grades from profiles: MICC A- (3.68), MRP B (2.70); MFP first score B+ (3.23)
  • 🔁 Ratings: VYLR SELL ($54, first listed rating); SNDK HOLD → TRIM (≈$914); MFP, OCTV, RAL HOLD → TRIM ($35 / $19 / $58); FDXF HOLD → TRIM ($112); HONA BUY → ACCUMULATE ($192); VGNT BUY → ACCUMULATE ($48); MRP BUY → HOLD, on watch ($25); AMTM BUY → ACCUMULATE ($25, price); VSNT ACCUMULATE held on a $36 target
  • 🔁 Targets: MBGL $27, Q $123, SOLS $57, ADIG $16, OCTV $19 (proposed), MFP $35 (first)
  • ⚠️ Barrick: no F-1; moved to Q1 2027
  • ⚠️ Sale alternatives live: International Paper, Solventum, Textron; J&J’s S&N combination dropped

APPENDIX A: COMPLETE SPINOFF LIST (October 2026)

#ParentSpinCoStructureFeaturesRevenueExpectedStatusGrade
1ComcastNBCUniversalClassic SpinoffRetained Stake≈$40B+≈Mid-2027Form 10 pending; retains ≤19.9%; buybacks suspendedB+
2Genuine PartsMotionClassic SpinoffNone≈$9BQ1 2027GPC CEO to Motion; no Form 10B+
3FlexAxiom (AXM)Classic SpinoffRetained Stake · Anchor Investor$6.6BQ1 2027EGM Nov 2; $2.0B preferred (General Catalyst, Koch); Flex keeps 6–12%B+
4Barrick MiningNorth American BarrickIPO Carve-OutRetained Stake≈$5.2B⚠️ Q1 2027No F-1; 10–15% floatB+
5KDPGlobal Coffee CoClassic SpinoffNone≈$16BEarly 2027CEO Russ Torres from Nov 3B+ ⬆️
6KBRTrinzic (TZIC)Classic SpinoffRetained Stake$5.3BJan 4, 2027Form 10 Sep 30; investor day Nov 12B
7EatonMobility Group + DanaRMTNone$3.1B (≈$11B combined)End Q1 2027S-4 Oct 19; Dana vote Dec 7B
8AbbottNutritionClassic SpinoffNone≈$8.5BBy end-2027Announced Oct 21 (NEW)B 🆕
9National Fuel GasIntegrated Upstream & GatheringClassic SpinoffRetained Stake≈69% of NFG EBITDAH2 2027Board approved Oct 14 (NEW)B 🆕
10UnileverFoods/McCormick RMTRMTNone≈$45B dealMid-2027CMA Phase 1 to Nov 11B
11McKessonMedical-Surgical (Wellverse)IPO Carve-OutAnchor Investor$11.4BH2 2027Apollo ≈13%B
12J&JDePuy SynthesClassic SpinoffNone≈$9.3BMid-2027Spin preferred; S&N talks droppedB
13HF SinclairLubricants & SpecialtiesClassic SpinoffRetained Stake≈$2.3B2027≥80.1% distributedB
14International PaperDS Smith plc (EMEA)Classic SpinoffRetained Stake · Dual-Listed≈$8.5B⚠️ Q1 2027 or saleSale talks confirmed Oct 15; Q3 EMEA lossB- ⬇️
15L3HarrisMissile Solutions (MSL)IPO Carve-OutRetained Stake · Anchor Investor≈$4.1B⚠️ Mid-2027IPO assumed before Dec 31, 2027B-
16TextronIndustrial (Kautex + TSV)Classic SpinoffNone≈$3BQ2–Q3 2027Sale or spin undecidedB-
17Adaptive BiotechImmune MedicineTBD—Early-stageYE 2026 pathPath due by year-endB-
18SolventumHealth Information SystemsTBD—≈$1.36B≈H2 2027Bids reported $5.5–7BB-
19Spectrum BrandsHome & Personal CareClassic SpinoffAnchor InvestorTBDIndefiniteOaktree ≈27.3% of HPCC+
20S&P GlobalCapital IQ and data businessesTBD—TBDNo timetableStrategic review (NEW)—
21SilganMetalCoTBD—TBD≥2 yrs after JV closeSpin is an option (NEW)—
22Vivani MedicalCortigent HoldingsTBD—Micro-capTBDVia ClearOne merger; not closed—
23Pineapple FinancialMortgage brokerageTBD—Micro-capTBDSpecial committee (NEW)—

Sort: by investment grade (highest first), matching the Part 2 ranking; ungraded names last. In the Features column None = checked, no feature applies; — = not yet classifiable.

Completed / now-trading spinoffs and their full post-spin performance are tracked in Part 3, Tables A–D — not duplicated here.

Completed This Cycle: MSG Sports → MSG Rangers (Oct 26; Classic Spinoff · Dual-Class); Medtronic → MiniMed full exit (Oct 15; Split-Off); Corteva → Vylor (Oct 1; Classic Spinoff); Modine → Performance Technologies/Gentherm (Oct 1; RMT); Toro → AI OKTO (Oct 8; Classic Spinoff; micro-cap; Toro keeps $25M of AIOK convertible preferred — recorded here, not as a feature, since the parent holds no common).

Removed / Reclassified / Paused / Canceled:

  • Jet.AI → Data Center Co. (DCTR): non-binding LOI lapsed without a definitive agreement; no filing since August 14 (removed this edition)
  • Click Holdings → Logistics: not mentioned in the October 22 20-F (removed this edition)
  • ⚠️ Kraft Heinz → 2-way split: paused indefinitely (prior)
  • ⚠️ Teleflex → NewCo: converted to outright sales (prior)
  • ABB → ABB Robotics: SoftBank sale (prior)
  • WBD → Discovery Global: ended; Paramount’s takeover completed October 6
  • Topgolf Callaway: converted to a sale (prior)
  • CSL Seqirus: postponed indefinitely (prior)
  • Trump Media → Truth Social: paused; the TAE merger S-4 (amended October 29) keeps the post-merger spin language
  • Microsoft → Xbox: rumor only (prior)
  • Non-US separations monitored but not individually tracked: SoftBank → Roze, ABF → Primark (Dec 2027), Siemens Energy → Transformation of Industry, Baidu → Kunlunxin, Jollibee → JFC International (Hong Kong), Evotec → Just Biologics, UPM → WISA Group (effective Oct 31), Tamarack/Headwater → Tributary Exploration (mid-Q4), thyssenkrupp → tk accelis (completed Oct 28), Informa → Taylor & Francis (NEW), Stora Enso → Bergslagets Skogar, Liberty Global → Ziggo (NEW), NGEx → Valiente (NEW), China Travel → CTG HK & Macao (NEW)

APPENDIX B: SPINOFF CLASSIFICATION REFERENCE

Every separation in this report carries one Structure — how the deal was done, legally and mechanically — and zero or more Features that modify it. Labels record the mechanics of each deal only. Definitions follow the Uncovering Value spinoff categories (vocabulary as of September 10, 2026).

Structure — exactly one per separation

StructureDefinitionDeciding questionIn this report
Classic SpinoffParent distributes SpinCo shares pro-rata to its shareholders as a dividend-in-kind and continues as a listed company. No merger, acquisition or restructuring is part of the separation. Typically tax-free under §355. No new capital. How much of SpinCo is distributed is a feature (Retained Stake), not part of the structure.Did every parent shareholder receive shares automatically, without electing?CMCSA → NBCUniversal, GPC → Motion, FLEX → Axiom, KDP → Global Coffee, KBR → Trinzic, ABT → Nutrition, NFG → IUG, JNJ → DePuy Synthes, DINO → Lubricants, IP → DS Smith, TXT → Industrial, SPB → HPC, TORO → AI OKTO; MSGR, VYLR, ADIG, MFP, MBGL, HONA, FDXF, NVRI, OCTV, TRAX, VGNT, VSNT, MICC, Q, SOLS, RAL, SNDK, MRP, ECG, SOBO
IPO Carve-OutSpinCo sells a minority stake via IPO; parent keeps the majority (typically 80–90%). Raises capital, taxable at IPO, separation deferred.Was there an IPO, and did the parent still hold a majority afterwards?B → North American Barrick, MCK → Medical-Surgical, LHX → MSL; JAN, MMED
Split-OffShare-exchange tender — holders choose to swap parent shares for SpinCo shares.Did shareholders have to elect?MDT → MiniMed (full exit) (completed this cycle)
RMTReverse Morris Trust. The spun business simultaneously merges with an unrelated public company; both shareholder bases own the result.Did the SpinCo merge into an existing public company on day one?ETN → Mobility/Dana, UL → Foods/MKC; THRM, CHRN, WAT, AMTM
Parent SplitThe parent itself ceases to exist, dissolving into two or more successors. There is no RemainCo.Does the original listed entity still exist?STRZ, LION
Pre-Acquisition SpinA parent being acquired carves out an asset the acquirer does not want, before the deal closes.Was the parent itself under an agreed acquisition at the time?RNA
DistressedPart of a Chapter 11 or cross-border restructuring; creditors typically receive the higher-quality entity.Was the separation ordered or negotiated inside a restructuring?—

Features — zero or more, on any structure

FeatureDefinitionIn this report
TaxableDistribution does not qualify for tax-free §355 treatment; holders taxed on receipt.NVRI
Paired SaleParent sells one business for cash at or near the same time as spinning another.NVRI
Retained StakeThe parent itself keeps a meaningful stake after the separation. A holder of the parent receiving its pro-rata shares does not count, however large.CMCSA → NBCUniversal, FLEX → Axiom, B → North American Barrick, KBR → Trinzic, NFG → IUG, DINO → Lubricants, IP → DS Smith, LHX → MSL; FDXF, AMTM
Multi-WayThree or more successor entities, simultaneous or staged.HONA
Dual-ListedLists on two or more exchanges concurrently.IP → DS Smith; OCTV
Dual-ClassUnequal voting rights, typically preserving family or founder control.MSGR, VSNT
REITFormed or re-formed as a real estate investment trust.JAN, MRP
MLPFormed as a master limited partnership.—
Anchor InvestorA government, strategic partner or PE holder takes a position at or near separation.FLEX → Axiom, MCK → Medical-Surgical, LHX → MSL, SPB → HPC

TBD: an upcoming separation whose structure the company has not yet chosen. In Appendix A, None means checked and no feature applies; — means not yet classifiable.

Labelling notes for this edition (outside the template).

  • New labels. Axiom gains Anchor Investor for the $2.0B General Catalyst / Koch preferred (8-K October 5). HF Sinclair’s Lubricants gains Retained Stake on the 10-Q’s “at least 80.1%” language, the same test applied to Trinzic. NFG → IUG takes Retained Stake from its 8-K.
  • Completed names. MSGR moves from the upcoming list to the completed names, keeping Classic Spinoff · Dual-Class. MiniMed’s full exit is recorded as a completed Split-Off; its trading row stays IPO Carve-Out, per the staged-separation rule.
  • CHRN is still carried without Retained Stake, matching the universe file, although Applied Digital itself holds ≈97%. That flag from September remains open.
  • The site’s September 29 RMT ruling (the counterparty need not be public) left the categories table row “kept as written”, so the definition above is unchanged.

Report Generated: October 31, 2026 (priced at the October 30, 2026 close, the last trading day before the report date)

Pricing: All stock prices as of the October 30, 2026 close. The companion site’s nightly series (run October 31) carried the October 30 bar for every tracked SpinCo; prices for upcoming-name parents not in that universe were pulled directly from yfinance, and the two sources agreed on every overlapping name checked.

  • Provider rescales: CTVA ×6.665 (October 1) and MSGK ×1.328 (October 27). Returns for both parents are measured from post-spin closes.
  • Sandisk’s 8-for-1 split takes effect after this report.

Next Update Recommended: Late November / early December 2026, after:

  • the November results cluster (Q, SOLS, VGNT, RAL, SOBO on November 4; ADIG, MBGL, OCTV on November 12);
  • the Flex EGM (November 2), CMA Phase 1 (November 11) and Trinzic investor day (November 12);
  • Millrose’s 10-Q, which decides its watch.

The most important pending item is not dated: the Seventh Circuit’s decision on the Vylor/Corteva TRO. It determines whether Vylor, graded A-, can return capital at all.

Methodology: Built primarily from company IR websites and SEC filings (Form 10 / 10-12B, S-4, 8-K, 10-Q, 10-K, 20-F, 6-K, DEF 14A, Rule 425, Schedule TO), press releases and financial news, supplemented by “upcoming spinoffs” searches, an EDGAR sweep of every Form 10-12B and 10-12B/A filed in October (none was filed by a tracked or new corporate spin), and the community trackers.

  • This report is the companion to uncoveringvalue.com, which publishes these reports alongside standing company profiles: full primary-source analyses of individual spinoffs, with scorecards, scenario valuations and price targets, updated between editions. Throughout this report, “the site” (including “the companion site”) refers to uncoveringvalue.com.
  • Grades, dimension scores and price targets for completed names are reconciled to those company profiles, read in full before drafting. New this cycle:
    • Vylor (Oct 1)
    • Mobility Global (Oct 5/9/14)
    • Versigent (Oct 6/8/15)
    • Honeywell Aerospace (Oct 6/13/29)
    • Versant (Oct 5/7/13)
    • Qnity (Oct 9/15)
    • Magnum Ice Cream (Oct 9/16/30)
    • Millrose (Oct 11/13/30)
    • Solstice (Oct 15)
    • ADI Global and Sandisk (Oct 23)
    • Octave (Oct 26)
    • Midera (Oct 28)
    • FedEx Freight (Oct 30)
    • Amentum (the Oct 20 correction)
  • Lag windows: for each profile, the window from its price date to October 30 was checked for events. The report owns the ratings that resulted: AMTM on price; VSNT on the scale; VYLR SELL on price and the TRO; MFP, OCTV and RAL TRIM on price; SNDK TRIM on the pending re-strike.
  • Primary filings were pulled from EDGAR for every name whose grade moved or was first set: KDP’s CEO 8-K; International Paper’s Q3 10-Q; Abbott’s and National Fuel Gas’s announcement 8-Ks; Eaton/Mobility’s S-4 and Dana’s Rule 425. Also pulled: the Flex preferred, EPC and proxy filings; MiniMed’s final exchange results; the MSG completion 8-Ks; the Gentherm/Modine closing 8-Ks; and the Vylor and Corteva TRO 8-Ks.
  • The Investment Scorecard applies the five-dimension weighted framework (Financial 25%, Competitive 25%, Strategic 20%, Management 20%, Acquisition 10%; 1–5 per dimension), mapped to letter grades per the Spinoff Investment Analysis Skill methodology.
  • Ratings use the five-band scale adopted with this report (see the opening note).

Source: Spinoff Investment Analysis Skill v4.0


SOURCES

Completed Spinoffs — October 2026

Upcoming Spinoffs — Primary Sources

Completed-Spinoff Developments

Standing Company Profiles (uncoveringvalue.com)

  • October 2026: Vylor, Mobility Global, Versigent, Honeywell Aerospace, Versant, Qnity, Magnum Ice Cream, Millrose, Solstice, ADI Global, Sandisk, Octave Intelligence, Midera Food Processing, FedEx Freight, the Amentum correction; the MSG Rangers / Knickerbockers pre-spin analysis (draft, no scorecard). Carried from earlier editions: Ralliant, Everus, South Bow.

Online Community Corroborative Sources


DISCLAIMER

This report is for informational and educational purposes only. Not investment advice. Spinoff transactions are subject to change, delay, or cancellation. This cycle alone saw:

  • a restraining order on dividends and buybacks issued against a SpinCo eight days after it began trading (Vylor);
  • a parent confirming sale talks for the business it had just named for listing (International Paper);
  • a $2.0B preferred with a redemption clock placed ahead of a SpinCo’s common before it trades (Flex/Axiom);
  • final transaction terms that differed from those announced two weeks earlier (Modine/Gentherm).

Stock prices referenced are as of the October 30, 2026 close (verified daily data via yfinance).

Where a parent has undergone a corporate action that distorts comparison, this is footnoted and the affected figures are shown adjusted or marked “n/m”. This edition adds the provider rescales for Corteva (×6.665, October 1) and MSG Knickerbockers (×1.328, October 27). Sandisk’s 8-for-1 split (effective November 20) will apply to every Sandisk figure in the next edition.

Corrections recorded in this edition.

  • Vylor: the first regular-way close was $68.26 (15.0M shares, after the closing auction), not ≈$69. (Vylor profile.)
  • Modine/Gentherm: the closing figures were $155,991,275 of cash to Modine and a $2.07 special dividend ($63.5M). The September 17 announcement, which this report printed, gave $159M and $1.90. (Closing 8-Ks.)
  • MSG Rangers: FY2026 pro-forma adjusted operating loss $(21.5)M, not $(16.3)M. (Form 10/A, September 30.)
  • Midera: net debt $208.1M, not ≈$0.3B; the September 30 EV multiple was ≈12.2x, not 12.8x. (Midera profile.)
  • Millrose: September’s “the land-bank model has not changed” omitted the rental-home amendments filed September 1. The March 2 report’s “Lennar retained ≈20%” was wrong; Lennar exchanged that stake in November 2025. (Millrose profile.)
  • Mobility Global: September’s fall was an auto-sector sell-off, not an information-services de-rating. MBGL is in the S&P SmallCap 600. (MBGL profile.)
  • Octave: the Day-1 base is the $17.05 first-day close, not a ≈$20.35 open. All Octave vs-Day-1 returns in earlier editions understate the return. (Octave profile.)
  • Qnity: the $43M cited in September is only the North Carolina share; Qnity has $253M recorded for its share of DuPont’s legacy liabilities. (Qnity profile.)
  • Versant: debt principal $3.0B, not $3.2B; underlying revenue decline −4.1%, not −2.5%. (Versant profile.)
  • Solstice: a member of the S&P MidCap 400, not the S&P 500. (Solstice profile.)
  • Amentum / RMTs: “the universe’s worst structure” is not supported by the site’s October 20 study. RMTs trail classic spinoffs by 1.7 points a year, not significantly. (Amentum profile; analysis correction, no business change.)
  • J&J / DePuy: expected mid-2027 per the 10-Q, not H2 2027.
  • BD: analyst day December 10, not November.

Grade changes in this edition rest on primary documents filed this cycle.

  • KDP’s upgrade rests on its October 1 8-K.
  • International Paper’s downgrade rests on its Q3 10-Q and the October 15 confirmation of sale talks.
  • Eaton/Mobility’s first score rests on the S-4.
  • Abbott’s and National Fuel Gas’s first grades rest on their announcement 8-Ks and are provisional: neither has a Form 10.
  • The first grades for Magnum and Millrose, Midera’s first score and Vylor’s re-score come from company profiles built from 10-Ks, 10-Qs and information statements.

Open at the pricing date:

  • the Seventh Circuit’s ruling on the Vylor/Corteva TRO;
  • the Flex EGM;
  • the CMA Phase 1 decision;
  • Barrick’s F-1;
  • International Paper’s, Solventum’s and Textron’s sale processes;
  • Millrose’s watch.

Always conduct your own due diligence and consult with financial advisors before making investment decisions. Past spinoff performance does not guarantee future results.